Pet tracer compounds for tracing alpha-galactosidase a and reaction intermediates, and methods of use

Novel PET tracer compounds enable non-invasive, real-time monitoring of α-Galactosidase A expression in Fabry disease patients, addressing the need for reliable and non-invasive imaging by specifically binding to α-Galactosidase A and utilizing PET technology for effective gene therapy monitoring.

WO2024236544A1PCT designated stage expired Publication Date: 2024-11-21TAKEDA PHARMA CO LTD +5
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054827
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-02
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods for monitoring gene delivery and expression in patients with Fabry disease, such as fluorescence imaging, are invasive and not clinically feasible for repeated biopsies, necessitating a non-invasive and reliable imaging tool for real-time tracking of α-Galactosidase A expression.

Method used

Development of novel PET tracer compounds that specifically bind to α-Galactosidase A, utilizing bioorthogonal chemical reactions and radioactive moieties for positron emission tomography (PET) imaging, allowing for non-invasive and real-time monitoring of α-Galactosidase A expression levels and activities in patients receiving gene therapy.

Benefits of technology

Enables effective, non-invasive tracking of α-Galactosidase A expression and enzymatic activities in patients with Fabry disease, enhancing the monitoring of gene therapy efficacy and improving clinical protocols through real-time imaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2024054827_21112024_PF_FP_ABST
    Figure IB2024054827_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides, among other things, novel tracers, compositions for tracking expression levels and in vivo activities of α -galactosidase A (α -Gal A) or a variant thereof. Those compounds specifically bind to α -galactosidase A. Use of those radiolabeled compounds for example in PET imaging, can monitor α -galactosidase A (α -Gal A) in a patient having Fabry disease after the patient receives an α -galactosidase A gene therapy or after an enzyme replacement therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. MIL-029WO1 PET TRACER COMPOUNDS AND REACTION INTERMEDIATES, AND METHODS OF USE CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No.63 / 573,324, filed on April 2, 2024, and U.S. Provisional Application No.63 / 502,761, filed on May 17, 2023, the contents of both of which are incorporated herein by reference in their entireties. BACKGROUND

[0002] Gene therapy is commonly used in treating and / or preventing enzyme deficiency diseases, by replacing the defective genes and / or imparting new functions to cells and tissue. For example, Fabry disease is a rare progressive congenital metabolic disease caused by a deficiency in the lysosomal enzyme α -galactosidase A (GLA) as a result of a mutation in the GLA gene. Adeno-associated virus (AAV) vector-based gene therapy has been developed for treating and / or preventing peripheral neuropathy in Fabry patients, where AAV is used to mediate transfer and expression of the GLA gene. Such gene therapy leads to continuous, endogenous expression of the α -galactosidase A protein, which is then transported to Fabry- affected tissues via the blood. In this context, it is important to understand the gene delivery and expression in patients, in order to develop efficient and reliable clinical practices.

[0003] To better understand the gene delivery and expression in patients, it is important to monitor the gene delivery and expression in real time. There are several imaging tools available, for example, fluorescence imaging. However, repeated biopsy and access to many relevant organs are not clinically feasible. Thus, a reliable and non-invasive imaging tool is desired.

[0004] Positron Emission Tomography (PET) is based on the detection of trace quantities of positron-emitting molecular moiety within cells post administration, permitting imaging of target molecules in vivo. This non-invasive and repeatable imaging tool is suitable for real time monitoring gene delivery and expression in pre-clinical and clinical studies, validating stages subsequent to vector administration and allowing for the improvement of clinical protocols. SUMMARY OF THE INVENTION

[0005] The present invention provides novel compounds and compositions thereof for use as PET tracers in tracking expression levels and in vivo activities of α -Galactosidase A orAttorney Docket No. MIL-029WO1 variant thereof in a subject. Those novel compounds and tracers specifically and selectively bind to α -Galactosidase A over other enzymes such as α -Galactosidase B. The present invention also provides methods of use of the novel compounds and tracers for monitoring α - Galactosidase A in vivo in a patient who has Fabry disease and optionally receives a α - Galactosidase A gene therapy (e.g., an AAV-GLA vector). The methods can be non-invasive and real time for monitoring the therapeutic efficacy of the gene therapy in Fabry patients.

[0006] In one aspect, the present invention provides a compound for use in tracing alpha- galactosidase A or variant thereof, wherein the compound has a structure according to Formula I, HO, wherein each of L1and L2is independently an optionally substituted C1-C20alkylene or a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety.

[0007] In some embodiments, the compound of Formula I, wherein A is a heterocylic compound comprising 1-3 nitrogen atoms.

[0008] In some embodiments of the compound of Formula I, wherein A is 1,2,3-triazole formed from an alkyne and an azide moiety. In some embodiments of the compound of Formula I, A is formed from strain-promoted azide-alkyne cycloaddition (SPAAC) reaction or inverse-electron-demand Diels–Alder (IEDDA) reaction. In some embodiments of the compound of Formula I, A is formed from strain-promoted azide-alkyne cycloaddition (SPAAC) reaction (e.g., with dibenzocyclooctyne (DBCO) as the alkyne). In some embodiments of the compound of Formula I, A is formed from inverse-electron-demand Diels–Alder (IEDDA) reaction (e.g., with tetrazine (Tz) / trans-cyclooctene (TCO)).Attorney Docket No. MIL-029WO1

[0009] In some embodiments, the compound of Formula I is formed from an azide- HO containing compound of Formula (Formula II), and anR alkyne-containing compound of Formula III,(Formula III).

[0010] In some embodiments, the a structure according to Formula I-A, HO(Formula I-A).

[0011] In some embodiments, the compound of Formula I, wherein L1is a C1-C10 alkylene; and / or L2is a C1-C5alkylene linker or a 6-20 membered heteroalkylene comprising one or two amide moieties.

[0012] In some embodiments, the compound of Formula I, wherein CH2 nwherein n is an integer of 1-10;O wherein m is an integer of 1-5, o is anAttorney Docket No. MIL-029WO1

[0013] In some embodiments, the compound of Formula I, wherein R is a radioactive moiety for use in positron emission tomography (PET).

[0014] In some embodiments, the compound of Formula I, wherein R is or comprises a moiety selected from18F,64Cu,89Zr,111In,99mTe,11C,14C,124I,123I,131I,15O,13N and82RbCl.

[0015] In some embodiments, the compound of Formula I is 2-(4-(3-(fluoro-18F)propyl)- 1,1,1,1,1,1-hexamethyl-1H-1λ9,2,3-triazol-1-yl)-1-((1S,2S,3S,4S,5R,6S)-2,3,4-trihydroxy-5- (hydroxymethyl)-7-azabicyclo[4.1.0]heptan-7-yl)ethan-1-one (Compound 1).

[0016] In some embodiments, the compound of Formula I has a structure of HO(Compound 1).

[0017] In some embodiments described herein, a radiolabeled protein, wherein said radiolabeled protein is formed by contacting a protein of interest with a compound according to Formula I as described in this application.

[0018] In some embodiments, the radiolabeled protein, wherein the said radiolabeled protein has a structure according to Formula IV,(Formula IV),Attorney Docket No. MIL-029WO1 wherein each of L1and L2is independently an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety.

[0019] In some embodiments, the radiolabeled protein of Formula IV, wherein each of L1and L2is independently an optionally substituted C1-C20alkylene or a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety.

[0020] In some embodiments, the radiolabeled protein of Formula IV, wherein A is a heterocylic compound comprising 1-3 nitrogen atoms.

[0021] In some embodiments, the radiolabeled protein of Formula IV, wherein A is 1,2,3- triazole formed from an alkyne and an azide moiety.

[0022] In some embodiments of the radiolabeled protein of Formula IV, A is formed from strain-promoted azide-alkyne cycloaddition (SPAAC) reaction or inverse-electron- demand Diels–Alder (IEDDA) reaction. In some embodiments of the radiolabeled protein of Formula IV, A is formed from strain-promoted azide-alkyne cycloaddition (SPAAC) reaction (e.g., with dibenzocyclooctyne (DBCO) as the alkyne). In some embodiments of the radiolabeled protein of Formula IV, A is formed from inverse-electron-demand Diels–Alder (IEDDA) reaction (e.g., with tetrazine (Tz) / trans-cyclooctene (TCO)).

[0023] In some embodiments, the radiolabeled protein of Formula IV, wherein L1is a C1- C10alkylene; and / or L2is a C1-C5 alkylene linker or a 6-20 membered heteroalkylene comprising one or two amide moieties.

[0024] In some embodiments, the radiolabeled protein of Formula IV, wherein R is or comprises a moiety selected from18F,64Cu,89Zr,111In,99mTe,11C,14C,124I,123I,131I,15O,13N and82RbCl.

[0025] In some embodiments, the radiolabeled protein of Formula IV, wherein R is18F.

[0026] In some embodiments, the radiolabeled protein of Formula IV is formed by contacting a protein of interest with a compound of Formula I that is Compound 1,Attorney Docket No. MIL-029WO1 HO, wherein the said radiolabeled protein has a structure according to Formula I-A-1,(Formula I-A-1).

[0027] In some embodiments, the radiolabeled protein of Formula IV is an α-Galactosidase A or a variant thereof.

[0028] In some embodiments described herein, a modified protein, wherein said modified protein is formed by contacting a protein of interest with a compound according to Formula II, HO(Formula II),Attorney Docket No. MIL-029WO1 wherein L1is an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene. C 029] In some embodiments, the modified protein, wherein L1 H[0 is2 n, wherein n is an integer of 1-10.

[0030] In some embodiments, the modified protein, wherein n is 7.

[0031] In some embodiments, the modified protein, wherein the protein is an alpha- galactosidase A or a variant thereof.

[0032] In some embodiments described herein, a radiolabeled protein, wherein said radiolabeled protein is formed by contacting a modified protein with a compound according to Formula III, 2 R H L(Formula III),L2is an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene; and R is a radioactive moiety.

[0033] In some embodiments, the radiolabeled protein, wherein R is or comprises a moiety selected from18F,64Cu,89Zr,111In,99mTe,11C,14C,124I,123I,131I,15O,13N and82RbCl.

[0034] In some embodiments, the radiolabeled protein, wherein R is18F.

[0035] In another aspect, the present invention provides a method for measuring alpha- galactosidase A or variant thereof in a subject; the method comprises administering to the subject a compound described herein and detecting a radioactive signal present in a target tissue of the subject based on the formation of a radiolabeled protein by binding of the compound to alpha-galactosidase A or variant thereof. As a non-limiting example, the compound administered to the subject is Compound 1.

[0036] In some embodiments, the method comprises administering first to the subject an unlabeled compound that binds to alpha-galactosidase A or variant thereof, for example, the compound of Formula II, subsequently administering to the subject a second compound of Formula III that comprises a radioactive moiety to form a radiolabeled protein (e.g., radiolabeled alpha-galactosidase A or variant thereof) and detecting a radioactive signal present in a target tissue of the subject based on the formation of the radiolabeled protein.Attorney Docket No. MIL-029WO1

[0037] According to the present method, the expression level of alpha-galactosidase A or variant thereof in a target tissue of the subject is measured. In addition, the enzymatic activities of alpha-galactosidase A or variant thereof in a target tissue of the subject is measured.

[0038] In some embodiments, the subject to be measured is diagnosed with Fabry disease.

[0039] In some embodiments, the subject receives an alpha-galactosidase A gene therapy. The gene therapy for Fabry disease comprises an AAV vector comprising a transgene encoding alpha-galactosidase A or a functional variant thereof.

[0040] In some embodiments, the target tissues include serum, heart, liver, lung, kidney, brain, spinal cord, stomach and gastrointestinal tract.

[0041] In some embodiments, the alpha-galactosidase A or variant thereof is measured about 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 6 months, one year, 2 years or more after the subject receives the alpha-galactosidase A gene therapy. In other embodiments, the alpha-galactosidase A or variant thereof is measured before the subject receives the alpha-galactosidase A gene therapy.

[0042] In some embodiments, the method described herein includes detecting the radioactive signal in the target issue by imaging the target tissue such as positron emission tomography (PET) imaging.

[0043] In some embodiments, the expression level and / or enzymatic activities of alpha- galactosidase A or variant thereof can be measured using real-time imaging.

[0044] In some embodiments, the relative amount of the radioactive signal in the target tissue is determined.

[0045] Other features, objects, and advantages of the present invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments of the present invention, is given by way of illustration only, not limitation. Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] The drawings are for illustration purposes only, not for limitation.

[0047] Figure 1 depicts the analytical HPLC gamma chromatogram, which was used for product radiochemical purity determination.Attorney Docket No. MIL-029WO1

[0048] Figure 2 is a representive [18F]AGAL PET imaging of representative mice at 6 and 26 weeks after AAV-based gene therapy, demonstrating increased radioactivity uptake in the heart of the AAVGLA-transduced mice.

[0049] Figures 3A, 3B, and 3C depict Compound 1 heart uptake in comparison with heart and serum α-Gal A activity. Figure 3A and 3B show quantification of the PET signal in the heart and determination of serum alpha galactosidase A (α-Gal) activity, showing higher [18F]AGAL uptake in the heart and serum α-Gal activity in the AAVGLA-treated mice. Three- digit numbers correspond to the animals’ identification numbers (WT: 555, 557, 558; AAVnull-treated: 559, 560, 561, 562; AAVGLA-treated: 563, 564, 565, 566). Figure 3C shows the [18F]AGAL heart uptake in AAVGLA-treated mice correlates with α-Gal activity in the heart and serum.

[0050] Figure 4A depicts the α-Gal A levels in liver and kidneys correlating with α-Gal activity in the serum indicating AAVGLAachieved transduction of clearance organs. Figure 4B and 4C depict Compound 1 PET signal in clearance organs liver (Figure 4B) and kidneys (Figure 4C).

[0051] Figures 5A and 5B depict the PET images using Compound 1 as PET tracer to measures α-Gal A levels during two scan sessions at week 6 and week 26 post gene therapy, respectively.

[0052] Figure 6A depicts the PET image of radiolabeled protein α-Gal A time activity curves of the two scan sessions at week 6 and week 26 post gene therapy, respectively.

[0053] Figures 6B and 6C show radioactivity concentrations in the heart at week 6 and week 26 post gene therapy, respectively. The left panels show [18F]AGAL uptake in the heart from 30 to 90 minutes at 6 weeks and 26 weeks after receiving gene therapy, respectively, showing higher retention in the AAVGLA-treated mice at both 6 and 26 weeks. The right panels show that Fabry mice that underwent gene therapy that encodes human alpha galactosidase A have higher [18F]AGAL uptake in their hearts. Data are displayed as means and standard deviations with illustration of individual datapoints.

[0054] Figure 6D show PET-based determination of the kinetics of [18F]AGAL in kidneys, liver, and heart, demonstrating time-activity uptake curves of major organs in GLA- KO mice 6 weeks after receiving gene therapy. Figure 6E show PET-based determination of the kinetics of [18F]AGAL in kidneys, liver, and heart, demonstrating time-activity uptake curves of major organs in GLA-KO mice 26 weeks after receiving gene therapy. The animals’ identifiers are depicted in the plots.Attorney Docket No. MIL-029WO1

[0055] Figure 6F shows quantification of the tracer’s levels in the heart, kidneys, liver and blood using a gamma counter. Data are displayed as means with illustration of individual datapoints. The animals’ identifiers are next to the corresponding datapoint. Statistical significance was determined using the Mann-Whitney test, and the p value is stated on top of the horizonal bar that compares the two groups. (%ID / g: percent injected dose of [18F]AGAL per gram of tissue / blood.

[0056] Figure 7A depicts representative PET images of murine heart slices incubated with 35 nM of [18F]AGAL for pH-based affinity study of Compound 1 binding to α-Gal A. The images indicate that the probe binds to the enzyme in acidic conditions (pH 5.0).

[0057] Figure 7B shows dynamics counts (MDC / mm2) in mice treated with 2 different gene therapy constructs. The data shows quantification of the autoradiography analysis of the images in Figure 7A, demonstrating 262-fold increased specific binding of [18F]AGAL to the hearts of Fabry mice transduced with AAVGLA.

[0058] Figure 7C shows In vitro characterization of the [18F]AGAL probe demonstrating binding to human alpha galactosidase A in the liver of transduced Fabry (GLA KO) mice. The upper panel is representative autoradiography images of mouse liver tissue sections incubated with [18F]AGAL at the corresponding pH, indicating that the probe binds to the enzyme in acidic conditions (pH 5.0). The lower panel is quantification of the autoradiography analysis, demonstrating increased specific binding of [18F]AGAL to the livers of Fabry mice transduced with rAAV-ubp-α-GalA. Data are displayed as means and standard deviations with illustration of individual datapoints. (MDC / mm2: molecular dynamic counts per square millimeter; GLA-KO: GLA knockout Fabry mice; rAAV-ubp-α-GalA: AAV encoding human alpha galactosidase A; Het. and Hom. Block: heterologous and homologous blocking respectively; Software-masked area represents part of the slice where the counts reached saturation).

[0059] Figure 7D shows In vitro characterization of the [18F]AGAL probe demonstrating binding to human alpha galactosidase A in the kidney of transduced Fabry (GLA KO) mice. The upper panel is representative autoradiography images of mouse kidney tissue sections incubated with [18F]AGAL at the corresponding pH, indicating that the probe binds to the enzyme in acidic conditions (pH 5.0). The lower panel is quantification of the autoradiography analysis, demonstrating increased specific binding of [18F]AGAL to the kidneys of Fabry mice transduced with rAAV-ubp-α-GalA. Data are displayed as means and standard deviations with illustration of individual datapoints. (MDC / mm2: molecular dynamic counts per square millimeter; GLA-KO: GLA knockout Fabry mice; rAAV-ubp-α-GalA:Attorney Docket No. MIL-029WO1 AAV encoding human alpha galactosidase A; Het. and Hom. Block: heterologous and homologous blocking respectively).

[0060] Figure 8 shows two separate saturation analysis of [18F]AGAL, which determines the equilibrium dissociation constant (KD) of [18F]AGAL using heart slices from AAVGLA- transduced Fabry mice and different concentrations of [18F]AGAL in two independent studies. Data are displayed as means and standard deviations with illustration of individual datapoints shown in Figure 7B.

[0061] Figure 9A is a representative PET scan showing mouse in each group (Groups A- C as indicated in Table 5) Imaging Day 0 (baseline) and Imaging Day 3 (blocking) post-gene- therapy (following intravenous administration of a heterologous or homologous blocking agent at 15 min before tracer injection).

[0062] Figure 9B is a representative [18F]AGAL PET scan showing mouse in each group (Groups A-C as indicated in Table 5) Day 28 (baseline) and Day 31 (blocking) post-gene- therapy.

[0063] Figure 10 shows the baseline of PET tracer binding (Day 0) and blocking by cold form of the probe [19F]AGAL for homologous blocking or an alpha-Gal A chaperon for heterologous blocking .

[0064] Figures 11A and 11B show changes in SUVmean30-60 of heart and liver from baseline imaging due to homologous blocking with [19F]AGAL or heterologous blocking with an alpha-Gal A chaperon . The alpha-Gal A chaperon and [19F]AGAL were dosed at 1 mg / kg. Group A: GLA-KO mice, untreated; Group B: GLA-KO mice, AAVGLA +heterologous blocking; Group C: GLA-KO mice, AAVGLA+homologous blocking. SUV: standardized uptake value. Each datapoint depicts the corresponding animal identifiers from each group.

[0065] Figures 12A and 12B show changes in AUC30-60 of heart and liver from baseline imaging due to homologous blocking with [19F]AGAL or heterologous blocking with an alpha-Gal A chaperon . The alpha-Gal A chaperon and [19F]AGAL were dosed at 1 mg / kg. Group A: GLA-KO mice, untreated; Group B: GLA-KO mice, AAVGLA +heterologous blocking; Group C: GLA-KO mice, AAVGLA+homologous blocking. AUC30-60: area-under- curve of 30 to 60 minutes post tracer dosing.

[0066] Figure 13A includes representative autoradiography images of heart, liver, and kidney sections incubated with [18F]AGAL at pH 5.0, indicating that the probe binds to the expressed enzyme in these organs of the AAVGLA-transduced mice.Attorney Docket No. MIL-029WO1

[0067] Figure 13B shows quantification of the autoradiography analysis, demonstrating increased specific binding of [18F]AGAL to the hearts and liver of Fabry mice transduced with AAVGLA. Lower specific binding was observed in the kidney. (MDC / mm2: molecular dynamic counts per square millimeter; Het. and Hom. Block: heterologous and homologous blocking respectively).

[0068] Figure 14 shows heart time-activity curves in GLA-KO mice after receiving gene therapy, where [18F]AGAL was administered 30 minutes before the homologous or heterologous blocking agent. PET-based determination of the kinetics of [18F]AGAL in the heart on Imaging Day 59 (59 days after dosing of AAVGLAas baseline).Heterologous blocking was done with an alpha-Gal A chaperon and homologous blocking was achieved using [19F]AGAL. The alpha-Gal A chaperon and [19F]AGAL were dosed at 1 mg / kg. AAVGLA- treated mice maintained high tracer uptake, suggesting that the tracer cannot be displaced by the blocking compound. The animals’ identifiers are depicted in the plots. (SUVmean: mean standardized uptake value; Het. and Hom. Block: heterologous and homologous blocking respectively).

[0069] Figure 15A shows coronal maximum intensity projection images of representative Fabry mice that received AAVGLAgene therapy or enzyme-replacement therapy. PET [18F]AGAL imaging was performed on two imaging days (Day 0: 28 days after gene therapy; Day 1: 24 hours after enzyme replacement therapy) showing higher radioactivity uptake in the heart of mice with AAVGLAgene therapy than enzyme replacement therapy.

[0070] Figure 15B shows Ex vivo determination of alpha galactosidase A (a-Gal) in the heart, showing higher enzyme activity levels in AAVGLA-treated mice. Statistical significance based on one-way ANOVA (**** p<0.0001; ns: not statistically significant).

[0071] Figure 15C shows correlation plot of the rank order of the [18F]AGAL in vivo heart uptake vs the ex vivo cardiac alpha galactosidase A activity (r: Pearson correlation coefficient). (SUV: standardized uptake value; WT: wildtype; AAVGLA: AAV encoding human alpha galactosidase A; ERT: enzyme replacement therapy; AUC: Area Under the time activity Curve derived from standardized uptake values between 30 to 60 min scan time).

[0072] Figures 16A-16F show PET-based determination of the retention of [18F]AGAL in the heart (16A), liver (16B), kidney (16C), lung(16D), gallbladder (16E), and bladder (16F). Higher uptake is observed in the heart, liver, and lung of gene-therapy-treated animals. Data are displayed as means and standard deviations.Attorney Docket No. MIL-029WO1

[0073] Figure 17 illustrates immunohistochemical evaluation of the heart of Fabry (GLA KO) mice for human alpha galactosidase A. Figures 17A to 17B shows representative immunohistochemistry images of heart tissue sections of animals that didn't undergo PET imaging 17A: alpha galactosidase A is detected 24 hours after enzyme replacement therapy (ERT).17B: The enzyme is detected in multiple cells 12 weeks after gene therapy, with pronounced staining observed in the mice that received AAVGLA. (AAVGLA: AAV encoding human alpha galactosidase A; CM: cardiomyocytes; IC: interstitial cells; α-Gal A positive staining (brown))...

[0074] Figure 18 shows GLA activity in the heart after transduction with different AAVGLAtiters. Gene therapy of double transgenic Fabry mice (G3Stg / GLA KO) induces dose-dependent expression of active alpha galactosidase A in the heart. Data are displayed as means and standard deviations with illustration of individual datapoints on panel.

[0075] Figures 19A and 19B show retest variability and Bland-Altman plot of [18F]AGAL. The tracer’s retest variability in the heart and liver was determined using AAVGLA-treated Fabry mice that were imaged on two consecutive days (Imaging Day 0 and 1) (Figure 19A). Tracers with retest variability under 10 % are considered excellent. In Figure 19B, in the Bland-Altman plot the solid middle line denotes the bias from zero, whereas the dashed lines depict the 95 % limits of agreement (i.e., bias ± 1.96 × standard déviation). Data are displayed as means and standard deviations with illustration of individual datapoints on panel A.

[0076] Figure 20 shows PET-based monitoring of the distribution of [18F]AGAL in a healthy non-human primate. Sagittal CT (top row), PET maximum intensity projection (middle row) and PET / CT fusion (bottom row) images of a male monkey, were taken at different times after [18F]AGAL administration. The tracer undergoes renal clearance, and elimination via the urinary bladder (UB).

[0077] Figure 21 shows time-activity uptake curves of [18F]AGAL in male rhesus monkey (Macaca mulatta). PET-based determination of the kinetics of [18F]AGAL in select organs following administration of the tracer. Figures 21A-21B depict the kinetics for the duration of the scan, whereas Figures 21C-21E show [18F]AGAL’s kinetics up to 2 hours after intravenous administration. (SUV: standardized uptake value; TACs: time-activity curves).Attorney Docket No. MIL-029WO1 DETAILED DESCRIPTION

[0078] The present invention provides novel compounds and compositions targeting α- Galactosidase, in particular α-Galactosidase A for use as tracers for tracking expression levels and in vivo activities of α-Galactosidase A or variant thereof in a subject. α-Galactosidase A and variants thereof may be expressed by a gene therapy vector that is administered to the subject. In some cases, α-Galactosidase A is endogenously expressed enzyme in the subject. The compounds and tracers can be used in combination with an α-Galactosidase A gene therapy, for example to monitor the therapeutic efficacy of the gene therapy. Definitions

[0079] In order for the present invention to be more readily understood, certain terms are first defined below. Additional definitions for the following terms and other terms are set forth throughout the specification. The publications and other reference materials referenced herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference.

[0080] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods, devices, and materials are now described. All technical and patent publications cited herein are incorporated herein by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0081] As used throughout the description, where compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that compositions of the present teachings also consist essentially of, or consist of, the recited components, and that the processes of the present teachings also consist essentially of, or consist of, the recited processing steps.

[0082] As used throughout the application, where an element or component is said to be included in and / or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements orAttorney Docket No. MIL-029WO1 components and can be selected from a group consisting of two or more of the recited elements or components.

[0083] As used in the description and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a composition” includes mixtures of two or more such compositions.

[0084] Throughout the description and claims of this specification the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps.

[0085] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0086] The term “approximately” or “about”, as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value). It is understood that when the term “about” or “approximately” is used to modify a stated reference value, the stated reference value itself is covered along with values that are near the stated reference value on either side of the stated reference value.

[0087] The variable groups defined herein, e.g., alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whether used alone or as part of another group, can be optionally substituted unless otherwise indicated. In embodiments, a variable group is unsubstituted. In embodiments, a variable group is substituted (e.g., comprising 1, 2, 3, 4, or 5 substituents (e.g., as described herein) and as valency and stability permits). Still further embodiments are described herein.

[0088] 18F: As used herein, the term “18F” refers to the radioactive isotope of Fluorine.

[0089] Administering: As used herein, the terms “administer”, “administration” and “administering” refer to providing a composition of the present invention (e.g., a recombinant gene therapy construct expressing α-Galactosidase A) to a subject in need thereof (e.g., to a person suffering from the effects of Fabry disease). "Administering to a subject" is aAttorney Docket No. MIL-029WO1 procedure by which one or more compounds or agents, together or separately, are introduced into or applied onto a subject.

[0090] Aliphatic: As used herein, the term aliphatic refers to hydrocarbons and includes both saturated and unsaturated hydrocarbons. An aliphatic may be linear, branched, or cyclic. For example, C1–C20 aliphatics can include C1–C20 alkyls (e.g., linear or branched C1–C20saturated alkyls), C2–C20alkenyls (e.g., linear or branched C4–C20dienyls, linear, or branched C6–C20trienyls, and the like), and C2–C20alkynyls (e.g., linear or branched C2–C20alkynyls). C1–C20 aliphatics can include C3–C20 cyclic aliphatics (e.g., C3–C20 cycloalkyls, C4–C20cycloalkenyls, or C8–C20cycloalkynyls). In certain embodiments, the aliphatic may comprise one or more cyclic aliphatic and / or one or more heteroatoms such as oxygen, nitrogen, or sulfur and may optionally be substituted with one or more substituents such as alkyl, halo, alkoxyl, hydroxy, amino, aryl, ether, ester or amide. An aliphatic group is unsubstituted or substituted with one or more substituent groups as described herein. For example, an aliphatic may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, - OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1–C20aliphatic (e.g., C1–C20alkyl, C1–C15alkyl, C1–C10alkyl, or C1–C3alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1–C20alkyl, C1–C15alkyl, C1–C10alkyl, or C1–C3alkyl). In some embodiments, R’ independently is unsubstituted C1–C3alkyl. In some embodiments, the aliphatic is unsubstituted. In some embodiments, the aliphatic does not include any heteroatoms.

[0091] Alkyl: As used herein, the term “alkyl” means acyclic linear and branched hydrocarbon groups, e.g., “C1–C20alkyl” refers to alkyl groups having 1–20 carbons and “C1- C4 alkyl” refers to alkyl groups having 1–4 carbons. Alkyl groups include C1–C20 alkyl, C1– C15 alkyl, C1–C10 alkyl, C1–C4 alkyl, and C1–C3 alkyl). In embodiments, an alkyl group is C1–C4alkyl. An alkyl group may be linear or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl tert-pentylhexyl, isohexyl, etc. The term “lower alkyl" means an alkyl group straight chain or branched alkyl having 1 to 6 carbon atoms. Other alkyl groups will be readily apparent to those of skill in the art given the benefit of the present disclosure. An alkyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, - OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instanceAttorney Docket No. MIL-029WO1 of R’ independently is C1–C20 aliphatic (e.g., C1–C20 alkyl, C1–C15 alkyl, C1–C10 alkyl, C1–C4 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20alkyl, C1–C15alkyl, C1–C10alkyl, or C1–C3alkyl). In some embodiments, R’ independently is unsubstituted C1–C3 alkyl. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and the like. In some embodiments, the alkyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). In some embodiments, an alkyl group is substituted with a–OH group and may also be referred to herein as a “hydroxyalkyl” group, where the prefix denotes the –OH group and “alkyl” is as described herein. In some embodiments, an alkyl group is substituted with a–OR’ group. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, 3-carboxypropyl, and the like. In substituent groups with multiple alkyl groups such as (C1-C6alkyl)2amino, the alkyl groups may be the same or different.

[0092] Alkylene: The term “alkylene,” as used herein, represents a saturated divalent straight or branched chain hydrocarbon group and is exemplified by methylene, ethylene, isopropylene and the like. Likewise, the term “alkenylene” as used herein represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along the chain, and the term “alkynylene” herein represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon triple bonds that may occur in any stable point along the chain. In certain embodiments, an alkylene, alkenylene, or alkynylene group may comprise one or more cyclic aliphatic and / or one or more heteroatoms such as oxygen, nitrogen, or sulfur and may optionally be substituted with one or more substituents such as alkyl, halo, alkoxyl, hydroxy, amino, aryl, ether, ester or amide. For example, an alkylene, alkenylene, or alkynylene may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or -SO2R’, wherein each instance of R’ independently is C1–C20aliphatic (e.g., C1–C20alkyl, C1–C15alkyl, C1–C10alkyl, or C1–C3alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1–C20 alkyl, C1–C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is unsubstituted C1–C3alkyl. In certain embodiments, an alkylene, alkenylene, or alkynylene is unsubstituted. In certain embodiments, an alkylene, alkenylene, or alkynylene does not include any heteroatoms.Attorney Docket No. MIL-029WO1

[0093] Alkenyl: As used herein, “alkenyl” means any linear or branched hydrocarbon chains having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along the chain, e.g., “C2-C20alkenyl” refers to an alkenyl group having 2–20 carbons. For example, an alkenyl group includes prop-2-enyl, but-2-enyl, but-3-enyl, 2- methylprop-2-enyl, hex-2-enyl, hex-5-enyl, 2,3-dimethylbut-2-enyl, and the like. In some embodiments, the alkenyl comprises 1, 2, or 3 carbon-carbon double bond. In some embodiments, the alkenyl comprises a single carbon-carbon double bond. In some embodiments, multiple double bonds (e.g., 2 or 3) are conjugated. An alkenyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkenyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, - OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1–C20aliphatic (e.g., C1–C20alkyl, C1–C15alkyl, C1–C10alkyl, or C1–C3alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1–C20 alkyl, C1–C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is unsubstituted C1-C3alkyl. In some embodiments, the alkenyl is unsubstituted. In some embodiments, the alkenyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). In some embodiments, an alkenyl group is substituted with a–OH group and may also be referred to herein as a “hydroxyalkenyl” group, where the prefix denotes the –OH group and “alkenyl” is as described herein. Nonlimiting examples of alkenyl groups include ethenyl, 3-propenyl, 1-propenyl (also 2-methylethenyl), isopropenyl (also 2-methylethen-2-yl), buten-4-yl, and the like. Nonlimiting examples of substituted alkenyl groups include 2-chloroethenyl (also 2-chlorovinyl), 4-hydroxybuten-1-yl, 7- hydroxy-7-methyloct-4-en-2-yl, 7-hydroxy-7-methyloct-3,5-dien-2-yl, and the like.

[0094] Alkynyl: As used herein, “alkynyl” means any hydrocarbon chain of either linear or branched configuration, having one or more carbon-carbon triple bonds occurring in any stable point along the chain, e.g., “C2–C20 alkynyl” refers to an alkynyl group having 2–20 carbons. Examples of an alkynyl group include prop-2-ynyl, but-2-ynyl, but-3-ynyl, pent-2- ynyl, 3-methylpent-4-ynyl, hex-2-ynyl, hex-5-ynyl, etc. In some embodiments, an alkynyl comprises one carbon-carbon triple bond. An alkynyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkynyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, - NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1–C20Attorney Docket No. MIL-029WO1 aliphatic (e.g., C1–C20 alkyl, C1–C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1–C15alkyl, C1–C10alkyl, or C1–C3alkyl). In some embodiments, R’ independently is unsubstituted C1–C3 alkyl. In some embodiments, the alkynyl is unsubstituted. In some embodiments, the alkynyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). Nonlimiting examples of alkynyl groups include ethynyl, prop-2-ynyl (also propargyl), propyn-1-yl, and 2-methyl-hex-4-yn-1-yl. Nonlimiting examples of substituted alkynyl groups include, 5-hydroxy-5-methylhex-3-ynyl, 6-hydroxy-6-methylhept-3-yn-2-yl, 5-hydroxy-5-ethylhept-3-ynyl, and the like.

[0095] Alkoxy: The term “alkoxy” refers to the group -O-alkyl, wherein the alkyl group is as defined above, including from 1 to 10 carbon atoms of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t- butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C1-4 alkoxy is an alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms. Unless stated otherwise in the specification, an alkoxy group can be optionally substituted by one or more substituents (e.g., as described herein for alkyl). The terms “alkenoxy” and “alkynoxy” mirror the above description of “alkoxy” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl" or “alkynyl” terms are as described herein.

[0096] Alkyne: The term “alkyne” as used herein, refers to a type of chemical compound contains at least one carbon-carbon triple bond. Internal alkynes feature carbon substituents on each acetylenic carbon. A terminal alkyne has one carbon from the carbon-carbon triple bond attached to a hydrogen, such as formula RC2H.

[0097] Aryl: The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 4 to 7 ring members. In some embodiments, an aryl group has 6 ring carbon atoms (“C6 aryl,” e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C10aryl,” e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C14aryl,” e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or moreAttorney Docket No. MIL-029WO1 carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Aryl groups can be unsubstituted or substituted. Exemplary aryls include phenyl, naphthyl, and anthracene. Aryl rings can be, for example, phenyl or naphthyl ring each optionally substituted with one or more moieties capable of replacing one or more hydrogen atoms. Non-limiting examples of aryl groups include: phenyl, naphthylen-1-yl, naphthylen-2-yl, 4-fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl, 2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert- butylphenyl, 3-methoxyphenyl, 8-hydroxynaphthylen-2-yl 4,5-dimethoxynaphthylen-1-yl, and 6-cyano-naphthylen-1-yl. Aryl groups also include, for example, phenyl or naphthyl rings fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa- 1,3,5-trienyl, indanyl), which can be substituted at one or more carbon atoms of the aromatic and / or saturated or partially saturated rings.

[0098] Arylalkyl: The term “arylalkyl” refers to an –(alkylene)-aryl radical where aryl and alkylene are as disclosed herein and which are optionally substituted by one or more of the exemplary substituent groups described herein. The “arylalkyl” group is bonded to the parent molecular structure through the alkylene moiety. The term “arylalkoxy” refers to an - O-[arylalkyl] radical (-O-[(alkylene)-aryl]), which is attached to the parent molecular structure through the oxygen.. Examples of arylalkyl groups include, for example, benzyl, 1- phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl and the like.

[0099] Arylene: The term “arylene” as used herein refers to an aryl group that is divalent (that is, having two points of attachment to the molecule). Exemplary arylenes include phenylene (e.g., unsubstituted phenylene or substituted phenylene).

[0100] Amide: The term “amide” or “amido” refers to a chemical moiety with formula C(O)N(R’)2, -C(O)N(R’)-, -NR’C(O)R’, or -NR’C(O)-, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated other-wise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring.

[0101] Amino: The term “amino” or “amine” refers to a -N(R’)2 group, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated otherwiseAttorney Docket No. MIL-029WO1 in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. In embodiments, an amino group is –NHR’, where R’ is aryl (“arylamino”), heteroaryl (“heteroarylamino”), or alkyl (“alkylamino”).

[0102] Azide: The term “azide” is defined herein as a linear, polyatomic anion with the formula N3- and structure−N=N+=N−.

[0103] Carbonyl: The term “carbonyl” refers to a -C(=O)R’, or -C(=O)- group, where R’is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, amino, hydroxyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, heterocycloalkyl (bonded through a ring carbon), unless stated other-wise in the specification, each of which moiety can itself be optionally substituted as described herein.

[0104] Cyclic: The term “cyclic” as used herein, refers to any covalently closed structure. Cyclic moieties include, for example, carbocycles (e.g., aryls and cycloalkyls), heterocycles (e.g., heteroaryls and heterocycloalkyls), aromatics (e.g., aryls and heteroaryls), and non- aromatics (e.g., cycloalkyls and heterocycloalkyls). In some embodiments, cyclic moieties are optionally substituted. In some embodiments, cyclic moieties form part of a ring system.

[0105] Cycloaliphatic: The term “cycloaliphatic” refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen and can be saturated or partially unsaturated. A cycloaliphatic group may be substituted or unsubstituted. Fully saturated cycloaliphatics can be termed “cycloalkyl”. Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or "cycloalkynyl" if the carbocycle contains at least one triple bond. Cycloaliphatic groups include groups having from 3 to 13 ring atoms (e.g., C3–13 cycloalkyl). Whenever it appears herein, a numerical range such as “3 to 10” refers to each integer in the given range, e.g., “3 to 10 carbon atoms” means that the cycloaliphatic group (e.g., cycloalkyl) can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 10 carbon atoms. The term “cycloaliphatic” also includes bridged and spiro-fused cyclic structures containing no heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic cycloaliphatic groups include bicycles, tricycles, tetracycles, and the like. In some embodiments, “cycloalkyl” can be a C3–8 cycloalkyl group. In some embodiments, “cycloalkyl” can be a C3–5cycloalkyl group. Illustrative examples of cycloaliphatic groups include but are not limited to the following moieties: C3–6cycloaliphatic groups include, without limitation, cyclopropyl (C3), cyclobutyl (C4),Attorney Docket No. MIL-029WO1 cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6) and the like. Examples of C3–7 cycloaliphatic groups include norbornyl (C7). Examples of C3–8cycloaliphatic groups include the aforementioned C3–7carbocyclyl groups as well as cycloheptyl (C7), cycloheptadienyl (C7), cyclohept-atrienyl (C7), cyclooctyl (C8), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like. Examples of C3-13 cycloaliphatic groups include the aforementioned C3-8carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl, and the like. Additional, nonlimiting examples of cycloaliphatic groups (including cycloalkyl groups) include: cyclopropyl, 2-methyl- cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5- trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a- hexahydro-3H-inden-4-yl, decahydroazulenyl; bicyclo[6.2.0]decanyl, decahydronaphthalenyl, dodecahydro-1H-fluorenyl, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl. A “bicycloalkyl” group includes bridged cycloalkyl groups such as bicyclo[1.1.1]pentyl, bicyclo[2.1.1]heptane, adamantanyl, and norbornanyl; as well as spiro cycloalkyl groups include spiro[3.3]heptane and spiro[4.5]decane. A “heterobicycloalkyl” group is a bicycloalkyl comprising at least one heteroatom in the ring framework.

[0106] Codon optimized: As used herein, the term “codon optimized” or “codon optimization” refers to changes in the codons of the polynucleotide encoding a protein (e.g., GLA gene) such that the encoded protein is more efficiently expressed, e.g., in a cell or an organism. In some embodiments, the polynucleotides encoding the α -GAL enzymes may be codon optimized for optimal production from the host organism(s) and / or cell type(s) selected for expression accounting for GC content, cryptic splice sites, transcription termination signals, motifs that may affect RNA stability, and nucleic acid secondary structures, as well as any other factors of interest. The terms “codon substitution” or “codon replacement” in the context of sequence optimization refer to replacing a codon present in a reference nucleic acid sequence with another codon. A codon can be substituted in a reference nucleic acid sequence, for example, via chemical peptide synthesis or through recombinant methods known in the art. Accordingly, references to a “substitution” or “replacement” at a certain location in a nucleic acid sequence (e.g., an mRNA) or within a certain region or subsequenceAttorney Docket No. MIL-029WO1 of a nucleic acid sequence (e.g., an mRNA) refer to the substitution of a codon at such location or region with an alternative codon.

[0107] Dose: As used herein, the terms "dose" and "dosage" are used interchangeably herein. A dose refers to the amount of active ingredient given to an individual at each administration. The dose will vary depending on a number of factors, including frequency of administration; size and tolerance of the individual; severity of the condition; risk of side effects; and the route of administration. One of skill in the art will recognize that the dose can be modified depending on the above factors or be based on therapeutic progress. The term "dosage form" refers to the particular format of the pharmaceutical, and depends on the route of administration.

[0108] Galactosidase: The term “galactosidase” or “α(alpha)-galactosidase A” or” α- galactosidase A” or “α-Gal A ”, as used herein, refers to the enzyme encoded by the GLA gene. Human alpha galactosidase (EC 3.2.1.22) is a lysosomal enzyme which hydrolyses terminal alpha galactosyl moieties from glycolipids and glycoproteins. As used herein, the term α-Gal A may refer to wild-type enzyme or a variant thereof. Deficiency of alpha galactosidase A causes Fabry disease (also referred to as angiokeratoma corporis diffusum, Anderson-Fabry disease, hereditary dystopic lipidosis, alpha-galactosidase A deficiency, α- Gal A deficiency, and ceramide trihexosidase deficiency), which is an X-linked inborn error of glycosphingolipid catabolism. In various embodiments described herein, a gene therapy platform is provided for treatment of Fabry disease.

[0109] Globotriaosylceramide: As used herein, the term “globotriaosylceramide”, “Gb3” or “GB3” or “gb3” or “CD77” or “GL-3” refers to a type of glycosphingolipid that accumulates in lysosomes in Fabry disease and is considered to be the main causative metabolite. De-acylatedGB3 or lysoGb3 is often used as a valuable biomarker for Fabry disease. Fabry disease is exemplified by accumulation of GB3 in in all organs (especially the heart and kidneys), as well as many cells and urine. Such accumulation is accompanied by a marked increase in the risk of stroke, heart disease (hypertrophic cardiomyopathy, rhythm and conduction system disorders, coronary artery disease, valve abnormalities, etc.) and chronic proteinuria renal failure.

[0110] GLA gene: As used herein, the term “GLA gene” or “galactosidase gene” or “alpha-galactosidase gene” or “α-galactosidase gene” refers to a gene which encodes for the enzyme alpha-galactosidase A that breaks down globotriaosylceramide. Genetic mutation in the GLA gene results in defective enzyme function of alpha-galactosidase.Attorney Docket No. MIL-029WO1

[0111] Half-Life: As used herein, the term “half-life” refers to the time required for a quantity such as the radioactive isotopes or activity to fall to half of its value as measured at the beginning of a time period. For example, the half-life of Fluorine-18 (18F) is 109.8 minutes.

[0112] Halogen: As used herein, the term "halogen" shall mean chlorine, bromine, fluorine, and iodine.

[0113] Heteroalkylene: The term “heteroalkylene” as used herein, represents a divalent form of a heteroalkyl group as described herein.

[0114] Heteroarylene: The term “heteroalkylene” as used herein, represents a divalent form of a heteroaryl group as described herein.

[0115] Heterocylic: The term “heterocyclic” refers to an organic compound containing a closed ring of atoms, at least one of which is not a carbon atom.

[0116] Heteroaryl: The term “heteroaryl,” as used herein, is defined herein as one or more rings having from 5 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), and wherein further at least one of the rings that includes a heteroatom is aromatic, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. In embodiments, “heteroaryl” refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, wherein each ring in the system contains 4 to 7 ring members, and wherein at least one ring atom is a heteroatom such as, but not limited to, nitrogen, oxygen, or sulfur. In heteroaryl groups that include 2 or more fused rings, the non-heteroatom bearing ring may be a carbocycle (e.g., 6,7-Dihydro-5H- cyclopentapyrimidine) or aryl (e.g., benzofuranyl, benzothiophenyl, indolyl). Exemplary heteroaryl groups have from 5 to 14 ring atoms and contain from 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heteroaryl group can be oxidized. Heteroaryl groups can be unsubstituted or substituted. The term “N-containing heteroaryl” refers to heteroaryl groups which comprise at least one nitrogen in the ring system (e.g., a heteroaryl comprising 1, 2, or 3 nitrogen atoms). In some embodiments, the foregoing groups, as derived from the groups listed above, are C- attached or N-attached where such is possible. Further, the term “heteroaryloxy” refers to the group -O-heteroaryl, where the group is attached to the parent molecular structure via the oxygen. Non-limiting examples of heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl,Attorney Docket No. MIL-029WO1 isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Non-limiting examples of heteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, furanyl, thiopheneyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4- dimethylaminopyridinyl. Non-limiting examples of heteroaryl rings containing 2 or more fused rings include: benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl, 9H-purinyl, 6-amino- 9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3- d]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, 1H- benzo[d]imidazol-2(3H)-onyl, 1H-benzo[d]imidazolyl, and isoquinolinyl. One non-limiting example of a heteroaryl group as described above is C1-C5 heteroaryl, which has 1 to 5 carbon ring atoms and at least one additional ring atom that is a heteroatom (preferably 1 to 4 additional ring atoms that are heteroatoms) independently selected from nitrogen (N), oxygen (O), or sulfur (S). Examples of C1-C5 heteroaryl include, but are not limited to, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-1-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.

[0117] Imaging: As used herein, the term “imaging” refers to the techniques and technologies that are used to view the subject in order to diagnose, monitor, or treat medical conditions.

[0118] Increased enzymatic activity: As used herein, the term “increased enzymatic activity” refers to an increase in specific activity (e.g., product produced / time / weight protein and biological function) or an increase in percent conversion of the substrate to the product (e.g., percent conversion of starting amount of substrate to product in a specified time period) using a specified amount of an α-Gal A enzyme or variant thereof as compared to a reference α-Gal A enzyme (e.g., a wild type α-Gal A enzyme or another engineered variant). Any suitable method known in the art and / or those described herein may be used to determine enzyme activity. Any property relating to enzyme activity may be affected, including the classical enzyme properties of Km, Vmaxor kcat, changes of which can lead to increased enzymatic activity. Improvements in enzyme activity can be from about 1.1 fold theAttorney Docket No. MIL-029WO1 enzymatic activity of the corresponding wild-type enzyme, to as much as 2-fold, 5 -fold, 10- fold, 20-fold, 25-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold or more enzymatic activity than a reference α-Gal A enzyme. The improved activity could also include any improved enzyme property or attribute of α-Gal A enzyme or an engineered variant thereof. Improved properties include, but are not limited to such properties as increased gene expression, increased protein production, increased thermoactivity, increased thermostability, increased activity at various pH levels, increased stability, increased enzymatic activity, increased substrate specificity or affinity, increased specific activity, increased resistance to substrate and / or product inhibition, increased chemical stability, improved chemoselectivity, improved solvent stability, increased tolerance to acidic, neutral, or basic pH, increased tolerance to proteolytic activity (i.e., reduced sensitivity to proteolysis), reduced aggregation, increased solubility, reduced immunogenicity, improved post-translational modification (e.g., glycosylation), altered temperature profile, increased cellular uptake, increased lysosomal stability, increased ability to deplete cells of GB3, increased secretion from α-Gal A producing cells, etc.

[0119] In vivo: As used herein, the term “in vivo” refers to events that occur within a multi-cellular organism, such as a human and a non-human animal. In the context of cell- based systems, the term may be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems).

[0120] Isotope: As used herein, the term “isotope” refers to a variant of a particular chemical element which differs in neutron number, and consequently in nucleon number. All isotopes of a given element have the same number of protons but different numbers of neutrons in each atom. For example, hydrogen has three naturally occurring isotopes, Protium, Deuterium and Tritium. An isotope may be radioactive and decays over time. For example, one of Fluorine’s isotope is18F, which is radioactive and emits positrons when decaying.

[0121] Moiety: The term “moiety” refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.

[0122] PET: As used herein, the term “PET” refers to Positron Emission Tomography (PET), which is a common imaging technique that uses radioactive substances (tracers) to visualize and measure changes in a subject, in pre-clinical and clinical studies.Attorney Docket No. MIL-029WO1

[0123] Prevent: As used herein, the term “prevent” or “prevention”, when used in connection with the occurrence of a disease, disorder, and / or condition, refers to reducing the risk of developing the disease, disorder and / or condition. See the definition of “risk.”

[0124] Protein: The term “protein” as used herein refers to one or more polypeptides that function as a discrete unit. If a single polypeptide is the discrete functioning unit and does not require permanent or temporary physical association with other polypeptides in order to form the discrete functioning unit, the terms “polypeptide” and “protein” may be used interchangeably. If the discrete functional unit is comprised of more than one polypeptide that physically associate with one another, the term “protein” refers to the multiple polypeptides that are physically coupled and function together as the discrete unit.

[0125] Subject: As used herein, the term “subject” refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate). A human includes pre- and post-natal forms. In many embodiments, a subject is a human being. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. The term “subject” is used herein interchangeably with “individual” or “patient.” A subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.

[0126] Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and / or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0127] Substituted: As used herein, the term “substituted” is defined herein as a moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several (e.g., 1 to 10) substituents as defined herein below. The substituents are capable of replacing one or two hydrogen atoms of a single moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety or unit. The variable groups defined herein, e.g., alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whether used alone or as part of another group, can be optionally substituted. Optionally substituted groups will be so indicated.Attorney Docket No. MIL-029WO1

[0128] Radioactive: As used herein, the term “radioactive” refers to a substance, or a moiety that contains such substance, that produces energy in the form of powerful rays.

[0129] Radiolabeled: As used herein, the term “radiolabeled” refers to any compound, or substance, or moiety, or protein, etc., which is connected to a radioactive isotope.

[0130] Tracer: As used herein, the term “tracer” refers to a positron-emitting radiopharmaceutical used in positron emission tomography (PET).

[0131] Triazole: The term “triazole” as used herein, refers to a group of chemical compounds with each having a five-membered ring of two carbon atoms and three nitrogen atoms. For example, 1,2,3-triazole is one type of triazole with the three nitrogen atoms adjacent to each other.

[0132] Therapeutically effective: A "therapeutically effective" amount or dose or "sufficient / effective" amount or dose, is a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques.

[0133] Treatment: As used herein, the term "treatment" or "therapy" generally means obtaining a desired physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or condition or symptom thereof and / or may be therapeutic in terms of a partial or complete cure for an injury, disease or condition and / or amelioration of an adverse effect attributable to the injury, disease or condition and includes arresting the development or causing regression of a disease or condition. Treatment can also include prophylactic use to mitigate the effects of injury, should it occur. Treatment can also refer to any delay in onset, amelioration of symptoms, improvement in patient survival, increase in survival time or rate, etc. The effect of treatment can be compared to an individual or pool of individuals not receiving the treatment.

[0134] Variants: The term “variants” or “engineered α-GAL variants” or “engineered variants” refers to α-GAL proteins, where, when compared to the wild-type α-GAL, one or more amino acid residues have been modified by substitution, deletion or insertion. In some embodiments, engineered variants are characterized by improved efficacy and pharmacokinetic profiles, due to, for example, modified the structural attributes of the protein. In some embodiments, engineered α-GAL variants enhance clearing of substrates from tissues, such as, serum, kidney, heart and / or liver. The engineered variants may be synthesized or produced recombinantly.

[0135] Vector: As used herein, the term “vector” is capable of transferring gene sequences to target cells. Typically, “vector construct,” “expression vector,” and “geneAttorney Docket No. MIL-029WO1 transfer vector,” mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning, and expression vehicles, as well as integrating vectors. In some embodiments, the vector is a virus (e.g., a recombinant virus with modifications), which includes, for example, encapsulated forms of vector nucleic acids, and viral particles in which the vector nucleic acids have been packaged. In some embodiments, vectors described herein are gene therapy vectors, which are used as carriers for delivery of polynucleotide sequences (e.g., an alpha galactosidase enzyme) to cells. In a particular embodiment, a gene therapy vector described herein is a recombinant AAV vector (e.g., AAV8 or AAV9). As used herein, the term “AAV vector” comprises a capsid protein and a viral genome, wherein the viral genome comprises at least one transgene region and at least one inverted terminal repeat (ITR). The AAV vector and / or its component capsid and viral genome may be engineered to alter tropism to a particular cell-type, tissue, organ or organism. In the context of the present invention, the viral genome comprises a GLA transgene, e.g., a nucleic acid sequence encoding α-GAL or variant thereof. I. α-Galactosidase A (α-Gal A; AGAL) tracer

[0136] In one aspect, the present invention provides novel compounds as PET tracers for tracking α-Galactosidase A, compositions thereof and methods of use thereof. The novel PET tracer compound of the present invention specifically binds to α-Galactosidase A (α-Gal A), providing a useful agent for measuring the expression level and / or enzymatic activities of α- Galactosidase A in a subject, for example a patient diagnosed with Fabry disease. Use of an enzyme specific tracer can be used in connection with gene therapy for Fabry disease. - Compounds

[0137] In one aspect of the present disclosure, a compound that can specifically bind to α- Galactosidase A (α-Gal A) is provided.

[0138] In some embodiments, an α-Galactosidase A (α-Gal A) tracer is a compound having a structure according to Formula I,Attorney Docket No. MIL-029WO1 HO (Formula I),are each independently according to any embodiment described herein, or any combination of embodiments.

[0139] In some embodiments, of Formula I: each of L1and L2is independently an optionally substituted C1-C20alkylene or a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety.

[0140] In some embodiments, the α-Gal A tracer according to Formula I, is a compound, wherein said compound is formed from an azide-containing compound of Formula II, HO

[0141] In some embodiments, the α-Gal A tracer is a compound having a structure according to Formula I-A, HO (Formula I-A).wherein each of L1, L2, and R is independently according to any embodiment described herein, or any combination of embodiments.Attorney Docket No. MIL-029WO1

[0142] Exemplary embodiments for each of L1, L2, A and R as present in any of Formula I-III and Formula I-A are described herein.

[0143] In some embodiments, L1is independently an optionally substituted C1-C20alkylene. In embodiments, L1is independently an unsubstituted C1-C20 alkylene. In some embodiments, L1is independently a substituted C1-C20 alkylene. In some embodiments, L1is independently CH2, (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9or (CH2)10. In some embodiments, L1is independently (CH2)7.

[0144] In some embodiments, L1is independently an optionally substituted C1-C10 alkylene. In some embodiments, L1is independently an unsubstituted C1-C10alkylene. In some embodiments, L1is independently a substituted C1-C10alkylene. In some embodiments, L1is independently CH2, (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9 or (CH2)10. In some embodiments, L1is independently (CH2)7.

[0145] In some embodiments, L1is independently an optionally substituted C2-C10alkylene. In some embodiments, L1is independently an unsubstituted C2-C10 alkylene. In some embodiments, L1is independently a substituted C2-C10 alkylene. In some embodiments, L1is independently (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9or (CH2)10. In some embodiments, L1is independently (CH2)7.

[0146] In some embodiments, L1is independently an unsubstituted C5-C10 alkylene. In some embodiments, L1is independently an unsubstituted C5-C10alkylene. In some embodiments, L1is independently a substituted C5-C10alkylene. In some embodiments, L1is independently (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9 or (CH2)10. In some embodiments, L1is independently (CH2)7. CH

[0147] In some embodiments, L1is2 n, wherein n is an integer of 1-20. In some CHembodiments, L1is2 n, wherein n is an integer of 1-10. In some embodiments, L1is CH2 n CH, wherein n is an integer of 2-10. In some embodiments, L1is2 n, wherein n isan integer of 5-10. In some embodiments, n is 2. In some n In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10.

[0148] In some embodiments, L1is independently an optionally substituted a 2-20 membered heteroalkylene. In some embodiments, L1is independently an unsubstituted a 2-20 membered heteroalkylene. In some embodiments, L1is independently a substituted a 2-20Attorney Docket No. MIL-029WO1 membered heteroalkylene (e.g., a 2-20 membered heteroalkylene comprising one or more oxo substituents).

[0149] In some embodiments, L1at least one heteroatom that is nitrogen. In some embodiments, L1comprises only nitrogen heteroatoms. In some embodiments, L1comprises amide functional groups (e.g., -NHC(O)- or -C(O)NH-). In some embodiments, L1has the O H following structure , where o and p are according to anyembodiments described herein. In some embodiments, o is an integer of 1-10 (e.g., o is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10). In some embodiments, p is an integer of 1-10 (e.g., p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10). O

[0150] In some embodiments, L1is independently ,wherein o is an integer of 1-5 and / or p is an integer of some o In some embodiments, o is 2. In some embodiments, o is 3. In some embodiments, o is 4. In some embodiments, o is 5. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4.

[0151] In some embodiments, L1at least one heteroatom that is oxygen. In some embodiments, L1comprises only oxy heteroatoms. In some embodiments, L1comprises an ethylene glycol repeating group.

[0152] In some embodiments, L2is independently an optionally substituted C1-C20 alkylene. In some embodiments, L2is independently an unsubstituted C1-C20 alkylene. In some embodiments, L2is independently a substituted C1-C20alkylene. In some embodiments, L2is independently CH2, (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9 or (CH2)10. In some embodiments, L2is independently (CH2)3.

[0153] In some embodiments, L2is independently an optionally substituted C1-C10alkylene. In some embodiments, L2is independently an unsubstituted C1-C10 alkylene. In some embodiments, L2is independently a substituted C1-C10 alkylene. In some embodiments, L2is independently CH2, (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9or (CH2)10. In some embodiments, L2is independently (CH2)3.

[0154] In some embodiments, L2is independently an optionally substituted C2-C10 alkylene. In some embodiments, L2is independently an unsubstituted C2-C10 alkylene. InAttorney Docket No. MIL-029WO1 some embodiments, L2is independently a substituted C2-C10 alkylene. In some embodiments, L2is independently (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9 or (CH2)10. In some embodiments, L2is independently (CH2)3.

[0155] In some embodiments, L2is independently an unsubstituted C2-C5 alkylene. In some embodiments, L2is independently an unsubstituted C2-C5 alkylene. In some embodiments, L2is independently a substituted C2-C5alkylene. In some embodiments, L2is independently CH2)2, (CH2)3, (CH2)4or (CH2)5. In some embodiments, L2is independently (CH2)3. CH

[0156] In some embodiments, L2is2 m, wherein m is an integer of 1-20. In some CHembodiments, L2is2 m, wherein m is an integer of 1-10. In some embodiments, L2is CH2m CH, wherein m is an integer of 2-10. In some embodiments, L1is2 m, wherein m is an integer of 2-5. In some embodiments, m is 2. In embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10.

[0157] In some embodiments, L2is independently an optionally substituted a 2-20 membered heteroalkylene. In some embodiments, L2is independently an unsubstituted a 2-20 membered heteroalkylene. In some embodiments, L2is independently a substituted a 2-20 membered heteroalkylene (e.g., a 2-20 membered heteroalkylene comprising one or more oxo substituents).

[0158] In some embodiments, L2at least one heteroatom that is nitrogen. In some embodiments, L2comprises only nitrogen heteroatoms. In some embodiments, L2comprises amide functional groups (e.g., -NHC(O)- or -C(O)NH-). In some embodiments, L2has the O following structure , where o and p are according to anyembodiments o is an integer of 1-10. In some embodiments, p is an integer of 1-10.Attorney Docket No. MIL-029WO1 O

[0159] In some embodiments, L2is independently ,wherein o is an integer of 1-5 and / or p is an integer of some o some embodiments, o is 2. In some embodiments, o is 3. In some embodiments, o is 4. In some embodiments, o is 5. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4.

[0160] In some embodiments, L2at least one heteroatom that is oxygen. In some embodiments, L2comprises only oxy heteroatoms. In some embodiments, L2comprises an ethylene glycol repeating group. 0161] In some embodiments, L1 CH[ is2 n, wherein n is an integer of 1-10; and O wherein m is an integer of 1-5, o is an- Bioorthogonal Reactions for Formation of Moiety A

[0162] In some embodiments, A is a moiety formed from a bioorthogonal chemical reaction to join the affinity ligand with the substructure comprising the radioactive moiety.

[0163] Bioorthogonal chemistry and bioorthogonal reactions each can refer to any chemical reaction that can occur inside of living systems without interfering with native biochemical processes. See, for example, Sletten et al., Angewandte Chemie International Edition.48 (38): 6974–98. doi:10.1002 / anie.200900942. PMC 2864149. PMID 19714693.). For example, bioorthogonal reactions can include click chemistry, which can refer to a class of simple, atom-economical reactions commonly used for joining two molecular entities of choice such as the exemplary azide-alkyne cycloaddition reactions described herein.

[0164] Exemplary, non-limiting bioorthogonal reactions include those known in the art, including the non-limiting examples described herein.

[0165] In some embodiments, a bioorthogonal reaction (e.g., a cycloaddition) comprises the use of a metal complex (e.g., a Cu-complex) to mediate the reaction.

[0166] In some embodiments, a bioorthogonal reaction (e.g., a cycloaddition) does not comprise the use of a metal complex to mediate the reaction.Attorney Docket No. MIL-029WO1

[0167] In some embodiments, a bioorthogonal reaction (e.g., a cycloaddition) comprises the use of photoactivation to mediate the reaction.

[0168] In some embodiments, a bioorthogonal reaction (e.g., a cycloaddition) comprises the use of ring strain to promote the reaction (e.g., a strain-promoted azide-alkyne cycloaddition reaction (SPAAC)).

[0169] In some embodiments, a bioorthogonal reaction is a metal-mediated (e.g., Pd) cross-coupling reaction between an arene and an alkene.

[0170] In some embodiments, a bioorthogonal reaction is a metal-mediated (e.g., Pd) cross-coupling reaction between an arene and an alkyne.

[0171] In some embodiments, a bioorthogonal reaction is a metal-mediated (e.g., Pd) cross-coupling reaction between two arenes to form a biaryl.

[0172] In some embodiments, a bioorthogonal reaction is a cycloaddition reaction, including but not limited to a Huisgen cycloaddition, a nitrone dipole cycloaddition, a norbornene cycloaddition, oxanorbornadiene cycloaddition, a [4+1] cycloaddition between an isocyanide and a tetrazine, or an inverse-electron-demand Diels–Alder reaction (IEDDA).

[0173] In some embodiments, a bioorthogonal reaction is a ligation reaction, including but not limited to a Staudinger ligation, a tetrazine ligation, an oxime ligation, or a quadricyclane ligation.

[0174] In some embodiments, a bioorthogonal reaction is a photocatalyzed click chemistry reaction (e.g., photoclick chemistry).

[0175] In some embodiments, a bioorthogonal reaction is a Huisgen cycloaddition between an azide moiety with an alkyne moiety. Azide-alkyne cycloadditions are a type of click chemistry. In particular, an azide functional group can provide favorable outcomes due to its high reactivity, less competing biological side reactions and relatively small size, which is favorable for cell permeability and avoids perturbations. In embodiments, an azide-alkyne cycloaddition is copper mediated (e.g., a Cu-mediated Click Chemistry reaction or a “CuAAC” cycloaddition). In embodiments, an azide-alkyne cycloaddition occurs in the absence of a copper catalyst (e.g., a Cu-free Click Chemistry reaction). In embodiments, an azide-alkyne cycloaddition is a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction. In embodiments, a SPAAC reaction comprises the use of dibenzocyclooctyne (DBCO) as the alkyne. Huisgen cycloadditions can provide moieties where A is a 1,2,3- triazole as described herein.Attorney Docket No. MIL-029WO1

[0176] In some embodiments, a bioorthogonal reaction is a dipole cycloaddition between a nitrone moiety with an alkyne moiety. In embodiments, such cycloadditions can provide moieties where A is an isooxazoline.

[0177] In some embodiments, a bioorthogonal reaction is a dipole cycloaddition between a nitrile oxide moiety with a norbornene moiety.

[0178] In some embodiments, a bioorthogonal reaction is a dipole cycloaddition between an azide moiety with an oxanorbornadiene moiety.

[0179] In some embodiments, a bioorthogonal reaction is a [4+1] cycloaddition between an isocyanide and a tetrazine.

[0180] In some embodiments, a bioorthogonal reaction is an inverse-electron-demand Diels–Alder(IEDDA) reaction. In some embodiments, an inverse-electron-demand Diels– Alder (IEDDA) reaction comprises the use of tetrazine (Tz) and / or trans-cyclooctene (TCO).

[0181] In some embodiments, a bioorthogonal reaction is a Staudinger ligation, comprising a reaction between an azide moiety with a phosphine moiety.

[0182] In some embodiments, a bioorthogonal reaction is a tetrazine ligation, comprising a reaction between a tetrazine moiety with an alkene (e.g., a trans-cyclooctene) moiety.

[0183] In some embodiments, a bioorthogonal reaction is an oxime ligation between an aldehyde or ketone moiety and a hydrazine (hydrazide) or alkoxyamine moiety to respectively form a hydrazone or an oxime.

[0184] In some embodiments, a bioorthogonal reaction is a quadricyclane ligation between a quadricyclane moiety and a π-system.

[0185] In some embodiments, a bioorthogonal reaction is a photoclick chemistry reaction between an alkene moiety and a tetrazole moiety.

[0186] In some embodiments, A is a moiety formed from an azide-based bioorthogonal chemical reaction. In embodiments, A is a moiety formed from a Click Chemistry reaction. In some embodiments, A is a moiety formed from a Cu-mediated Click Chemistry reaction. In some embodiments, A is a moiety formed from an azide-based and Cu-mediated Click Chemistry reaction.

[0187] In some embodiments, A is heterocylic compound comprising 1-3 nitrogen atoms. In some embodiments, A is heterocylic compound comprising one (1) nitrogen atom. In some embodiments, A is heterocylic compound comprising two (2) nitrogen atoms. In some embodiments, A is heterocylic compound comprising three (3) nitrogen atoms.Attorney Docket No. MIL-029WO1

[0188] In some embodiments, A is a moiety containing a triazole structure. In some embodiments, A is 1,2,3-triazole formed from an alkyne and an azide moiety. In N N embodiments, A has a structure - Radioactive Moieties

[0189] Various radioactive moieties are suitable for use in the invention. Exemplary, non- limiting radioactive moieties are described herein.

[0190] In some embodiments, R is a radioactive moiety. In some embodiments, R is a radioactive moiety for use in positron emission tomography (PET). In some embodiments, R is or comprises a radio-isotope of an element selected from fluorine, carbon, nitrogen, oxygen, iodine, copper, technetium, and rubidium. In some embodiments, R is or comprises a moiety selected from18F,64Cu,89Zr,111In,99mTe,11C,14C,124I,123I,131I,15O,13N and82RbCl.

[0191] In some embodiments, R is18F. In some embodiments, R comprises a moiety which contains18F.

[0192] In some embodiments, R is64Cu. In some embodiments, R comprises a moiety which contains64Cu.

[0193] In some embodiments, R is89Zr. In some embodiments, R comprises a moiety which contains89Zr.

[0194] In some embodiments, R is111In. In some embodiments, R comprises a moiety which contains111In.

[0195] In some embodiments, R is99mTe. In some embodiments, R comprises a moiety which contains99mTe.

[0196] In some embodiments, R is11C. In some embodiments, R comprises a moiety which contains11C.

[0197] In some embodiments, R is14C. In some embodiments, R comprises a moiety which contains14C.

[0198] In some embodiments, R is124I. In some embodiments, R comprises a moiety which contains124I.

[0199] In some embodiments, R is123I. In some embodiments, R comprises a moiety which contains123I.

[0200] In some embodiments, R is131I. In some embodiments, R comprises a moiety which contains131I.Attorney Docket No. MIL-029WO1

[0201] In some embodiments, R is15O. In some embodiments, R comprises a moiety which contains15O.

[0202] In some embodiments, R is13N. In some embodiments, R comprises a moiety which contains13N.

[0203] In some embodiments, R is82RbCl. In some embodiments, R comprises a moiety which contains82RbCl. - Exemplary Compounds

[0204] Exemplary compounds include those specifically described throughout the present disclosure, as well as any pharmaceutically acceptable form thereof (e.g., a pharmaceutically acceptable salt thereof).

[0205] In embodiments, a compound is 2-(4-(3-(fluoro-18F)propyl)-1,1,1,1,1,1- hexamethyl-1H-1λ9,2,3-triazol-1-yl)-1-((1S,2S,3S,4S,5R,6S)-2,3,4-trihydroxy-5- (hydroxymethyl)-7-azabicyclo[4.1.0]heptan-7-yl)ethan-1-one (Compound 1).

[0206] In embodiments, a compound is 2-(4-(3-(methoxy-11C)propyl)-1,1,1,1,1,1- hexamethyl-1H-1λ9,2,3-triazol-1-yl)-1-((1S,2S,3S,4S,5R,6S)-2,3,4-trihydroxy-5- (hydroxymethyl)-7-azabicyclo[4.1.0]heptan-7-yl)ethan-1-one (Compound 2).

[0207] Exemplary compounds include those of Table 1, as well as any pharmaceutically acceptable form thereof (e.g., a pharmaceutically acceptable salt thereof). Table 1 Example Compound No.StructureHO HO O (1) N N N HO7NOHFHO HO O (2) N N N HO N OHO CH- Radiosynthesis of PET Tracers and Synthetic Methods of Intermediates

[0208] Compounds described herein can be prepared according to methods known in the art.Attorney Docket No. MIL-029WO1

[0209] For example, the exemplary synthetic methods described in the instant Examples can be used to prepare still other compounds of the invention.

[0210] Accordingly, disclosed compounds can generally be synthesized by an appropriate combination of generally well-known synthetic methods and radiosynthesis systems. Techniques useful in synthesizing these chemical entities are both readily apparent and accessible to those of skill in the relevant art, based on the instant disclosure. Many of the optionally substituted starting compounds and other reactants are commercially available, e.g., from Aldrich Chemical Company (Milwaukee, Wis.) or can be readily prepared by those skilled in the art using commonly employed synthetic methodology. II. Protein-compound complex - Modified Protein

[0211] In some embodiments, a protein is radiolabeled via a stepwise fashion (e.g., by contacting first with a first compound comprising a first moiety suitable for use in a bioorthogonal reaction thereby forming a modified protein and then contacting the modified protein with a second compound comprising a second moiety suitable for use in a bioorthogonal reaction with said first moiety).

[0212] In some embodiments, a protein is modified, wherein said modified protein is formed by contacting a protein of interest with a compound according to Formula II, HO (Formula II),wherein each of L1is independently according to any embodiment described herein, or any combination of embodiments.

[0213] Exemplary embodiments for L1as present herein are described in this specification.

[0214] In some embodiments, a protein is modified, wherein said modified protein has a structure according to Formula V,Attorney Docket No. MIL-029WO1 Protein (Formula V).

[0215] In some embodiments, a protein is modified, wherein said modified protein is an α-Galactosidase A or a variant thereof. In some embodiments, the modified protein is a human α-Galactosidase A or variant thereof. In some embodiments, the modified protein is an engineered α-Galactosidase A or variant thereof. In other embodiments, the modified protein is a wild type α-Galactosidase A. In some embodiments, the modified protein is α- Galactosidase A or variant thereof expressed by a gene therapy product (e.g., a recombinant AAV-GLA gene therapy). In some embodiments, the modified protein is α-Galactosidase A or variant encoded by a therapeutic mRNA. - Radiolabeled Protein

[0216] In some embodiments, a protein is radiolabeled, wherein said radiolabeled protein is formed by contacting a protein of interest with a compound according to Formula I.

[0217] In some embodiments, a protein is radiolabeled, wherein said radiolabeled protein has a structure according to Formula IV, Protein (Formula IV),wherein each of L1, L2, A, and R are each independently according to any embodiment described herein, or any combination of embodiments.

[0218] In some embodiments, a protein is radiolabeled, wherein said radiolabeled protein is formed by contacting a modified protein, for example a protein having a structure according to Formula V,Attorney Docket No. MIL-029WO1 (Formula V),with a compound according to Formula III, 2 R H L (Formula III),wherein L2is an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene; and R is a radioactive moiety.

[0219] In some embodiments, of Formula IV: each of L1and L2is independently an optionally substituted C1-C20alkylene or a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety.

[0220] Exemplary embodiments for each of L1, L2, A and R as present in Formula IV are according to any embodiment described herein, or any combination of embodiments.

[0221] In some embodiments, a protein is radiolabeled, wherein said radiolabeled protein is formed by contacting a protein of interest with a compound of Formula (I) (e.g., according to any embodiment described herein) including, for example, Compound 1.Attorney Docket No. MIL-029WO1

[0222] In some embodiments, a protein is radiolabeled, wherein said radiolabeled protein has a structure according to Formula I-A-1, Protein (Formula I-A-1)

[0223] In some embodiments, a protein is radiolabeled, wherein said protein is an α‑Galactosidase A or a variant thereof. In some embodiments, the radiolabeled protein is a human α-Galactosidase A. In some embodiments, the radiolabeled protein is an engineered α- Galactosidase A. In other embodiments, the radiolabeled protein is a wild type α- Galactosidase A. In some embodiments, the radiolabeled protein is α-Galactosidase A expressed by a gene therapy product (e.g., a recombinant AAV-GLA gene therapy). In some embodiments, the radiolabeled protein is α-Galactosidase A encoded by a therapeutic mRNA. III. Compositions and kits

[0224] In another aspect of the present invention, a composition comprising one or more compounds described herein is provided.

[0225] In some embodiments, a composition is provided comprising at least one radiolabeled compound that binds to α-Galactosidase A.

[0226] In some embodiments, the composition may comprise a solution of one or more compounds described herein, such as a saline solution and / or an ethanol solution. In some embodiments, a solution comprising a radiolabeled compound is provided. In some embodiments, a solution comprising one or more compounds may be diluted, e.g., with water or saline. The composition may be put into a solution, e.g., for administration.

[0227] In one embodiment, the solution is an isotonic sterile injection solution. In one embodiment, the solution is PBS (Phosphate Buffered Saline) (1X, pH 7.4), with or without sodium ascorbate. In another embodiment, the solution is saline (0.9% NaCl), with or without sodium ascorbate.

[0228] In some embodiments, the composition can serve as a tracer in an imaging detection process, e.g., radiological or nuclear imaging, such as PET, SPECT, or otherAttorney Docket No. MIL-029WO1 radiological sensing and / or imaging, such as using a portable sensing device. In some embodiments, the composition can serve as a radiolabeled tracer.

[0229] In some embodiments, the composition comprises one or more compounds that are not labeled.

[0230] In some embodiments, the composition comprises a compound of Formula I.

[0231] wherein the compound has a structure according to Formula I, HO (Formula I), wherein each of L1and L2is independentlyor a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety. As a non- limiting example, the composition comprises Compound 1 HO (Compound 1).

[0232] In some embodiments, the composition comprises a compound of Formula II HO (Formula II),wherein L1is an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene.

[0233] In other embodiments, the present disclosure further provides a composition R comprising a compound of Formula III:H L(Formula III), wherein L2is anAttorney Docket No. MIL-029WO1 optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene and R is a radioactive moiety. Kits and Packages

[0234] In another aspect, the present disclosure provides kits and commercial packages comprising one or more compounds described herein, or any pharmaceutically acceptable forms thereof (e.g., any pharmaceutically acceptable salts thereof), or compositions as described herein.

[0235] In some embodiments, provided herein are kits. The kits can include a compound or pharmaceutically acceptable form thereof, or composition as described herein, in suitable packaging, and written material that can include instructions for use, discussion of clinical studies, listing of side effects, and the like.

[0236] Kits are well suited for the delivery of injectable solutions. Such kits can also include information, such as scientific literature references, package insert materials, clinical trial results, and / or summaries of these and the like, which indicate or establish the activities and / or advantages of the pharmaceutical composition, and / or which describe dosing, administration, side effects, drug interactions, or other information useful to the health care provider. Such information can be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. IV. Methods of use

[0237] The present disclosure also provides methods for measuring expression levels and in vivo activities of an enzyme or other molecules. More specifically, the tracers described herein which specifically bind and track α-Gal A are selected and radiolabeled. In some embodiments, the compound tracks the expression level of α-Gal A or a variant thereof in vivo. In some embodiments, the compound tracks in vivo activity of α-Gal A or a variant thereof.

[0238] In certain aspects, the compounds, tracers, compositions, and methods described herein are used in combination with gene therapy of a disease caused by α-Gal A deficiency such as Fabry disease. In some embodiments, the compounds, tracers and methods described herein are used to track the expression levels and in vivo activities of α-Gal A in a subject. The subject has Fabry disease. In some embodiments, the Fabry patient receives an α-Gal A gene therapy.Attorney Docket No. MIL-029WO1 - Fabry disease and gene therapy

[0239] Fabry disease is an X-linked inherited disease that results in the production of aberrant lysosomal hydrolase, α-galactosidase A (α-Gal A), due to mutations in the GLA gene. Because α-Gal A is necessary for catabolism of glycolipids, such as sphingolipids, deficiency or malfunction of α-Gal A causes accumulation of sphingolipids in tissues. Fabry diseases affects 1 in 40,000 males, who develop multisystem disease develops in childhood or adolescence.

[0240] Using a gene therapy vector to deliver a GLA transgene that encodes a functional enzyme (e.g., a wild type a α-Gal A or an engineered variant with enzymatic function) to Fabry patients has great advantages as compared to protein replacement therapy. One advantage of a gene therapy approach to the treatment of Fabry disease is continuous α-Gal A exposure rather than an intermittent α-Gal A exposure provided by ERT infusion.

[0241] The α-Gal A gene therapy vector may be a viral vector (e.g., lentivirus, retrovirus and adeno associated virus (AAV)). In some examples, the gene therapy vector is an AAV vector, e.g., a recombinant AAV vector. The AAV vector comprises a GLA transgene encoding α-Gal A or a variant thereof (e.g., a wild type or an engineered variant). In some embodiments, the gene therapy vector is optimized with respect to maximal gene expression. In some embodiments, the nucleic acid sequence encoding α-Gal A is codon-optimized. In some embodiments, the AAV vector further comprises an intrinsic expression system that improves the exposure or distribution of α-Gal A in various tissues; the improved exposure or distribution of α-GAL in various tissues improves the symptoms associated with Fabry disease. In some embodiments, the AAV vector results in broad, tissue-wide distribution of a wild type α-Gal A. In some embodiments, the AAV vector results in broad, tissue-wide distribution of a α-Gal A variant.

[0242] In some embodiments, the AAV vector comprises a ubiquitous promoter. In some embodiments, the AAV vector is selected from one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 or AAV9 having a ubiquitous promoter. In some embodiments, an appropriate AAV vector with wide tropism can be engineered with combined elements of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 or AAV9 having a ubiquitous promoter.

[0243] In other embodiments, the AAV vector comprises a tissue specific promoter. e.g., a liver specific promoter.Attorney Docket No. MIL-029WO1

[0244] In some embodiments, the AAV gene therapy vector is packaged in a AAV capsid having broad tissue tropism.

[0245] In some embodiments, the AAV gene therapy vector comprises a) a 5’ inverted terminal repeat (ITR); b) a ubiquitous promoter; c) a nucleotide sequence encoding α-GAL enzyme; d) a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE); e) a poly A; and f) a 3’ ITR.

[0246] In some embodiments, the AAV gene therapy vector comprises a GLA transgene disclosed in the PCT application publication WO2022 / 183052; the contents of which are incorporated herein by reference in their entirety.

[0247] In some embodiments, the Fabry patient receives a single dose of an AAV-GLA gene therapy. - Tracking α-Gal A in vivo

[0248] In accordance, α-Gal A levels in various target tissues of a subject are measured using a tracer described herein. In some embodiments, the subject is tested for α-Gal A expression levels and in vivo activities before receiving a gene therapy, e.g., 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, or one month before receiving an alpha-galactosidase A gene therapy (e.g., an AAV- GLA gene therapy).

[0249] In some embodiments, the subject is tested for α-Gal A expression levels and in vivo activities after receiving a gene therapy. As non-limiting examples, the subject is tested, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, one month, two months, five months, one year, 2 years, 3 year, 4 years, 5 years or longer after receiving an alpha-galactosidase A gene therapy (e.g., an AAV- GLA gene therapy).

[0250] In some embodiments, the method for measuring α-galactosidase A or variant thereof in vivo, comprises (a) administering a radiolabeled compound to a subject; and (b) detecting a radioactive signal present in a target tissue of the subject based on the formation of the radiolabeled α-Gal A or variant thereof. For example, the method comprises administering to the subject to be tested Compound 1: HO (Compound 1).Attorney Docket No. MIL-029WO1

[0251] In other embodiments, the method for measuring α-galactosidase A or variant thereof in vivo, the method comprising: (a) administering a compound of Formula II to the subject, wherein said compound of Formula II has the following structure, HO (Formula II), wherein L1is an optionally substituted C1-C20or a heteroalkylene; (b) administering a compound of Formula III to said subject, wherein said compound of Formula III has the following structure, RHL (Formula III), wherein L2is an optionally substituted C1-C20alkylene or a 2-20 membered heteroalkylene and R is a radioactive moiety to form a radiolabeled protein; (c) detecting a radioactive signal present in a target tissue of the subject based on the formation of the radiolabeled protein.

[0252] In some embodiments, the expression level of alpha-galactosidase A or variant thereof in a target tissue is measured. In some embodiments, the enzymatic activities of alpha-galactosidase A or variant thereof in a target tissue is measured. In some embodiments, the expression levels and enzymatic activities of alpha-galactosidase A or variant thereof in a target tissue is measured.

[0253] In some embodiments, the expression levels and / or enzymatic activities of alpha- galactosidase A or variant thereof are measured in, but not limited to heart, liver, lung, kidney, brain, spinal cord, stomach and gastrointestinal tract.

[0254] Any methods suitable for detection can be used, e.g., spectroscopic, photochemical, immunochemical, electronical, optical or chemical means. In some embodiments, the compounds are radiolabeled. Means for detecting labels are well known to those of skill in the art. For example, radiolabels may be detected using imaging techniques, photographic film or scintillation counters.

[0255] In some embodiments, the label is detected in vivo in a target tissue of the subject by imaging techniques, for example, position emission tomography (PET). In one embodiment, position emission tomography (PET) imaging is used. Any PET system can be used to perform imaging, for example the PET-600 system and PET / CT scanner. In some embodiments, the imaging detection process may be used to quantify and / or determine expression (e.g., levels, amounts, and / or densities) of α-Gal A or variant thereof in variousAttorney Docket No. MIL-029WO1 tissues of a subject. In some embodiments, the imaging detection process is used to quantify and / or determine expression (e.g., levels, amounts, and / or densities) of α-Gal A or variant thereof in the heart, liver, lung, kidney, brain, spinal cord, stomach and gastrointestinal tract of the subject. The expression levels in the tissues are detected simultaneously. In some embodiments, the imaging detection process is real time.

[0256] Accordingly, the present disclosure provides a method for determining the level of a tracer signal in a subject or patient before and / or after administration of a gene therapy construct. the level of the tracer signal is used to monitor the therapeutic effect. In some embodiments, the tracer comprises is coupled with a radioactive element, e.g.,18F,64Cu,89Zr,111In,99mTe,UC,14C,124I,123I,131I,150,13N and / or82RbCl. The radiolabeled tracer compound is use. In some embodiments, the tracer compound and the radioactive element are administered to the subject separately, which form a radiolabeled compound-protein complex. The radioactive signal is then detected and measured.

[0257] In some embodiments, the imaging detection process may be used to determine whether the α-Gal A or variant protein exceeds a predetermined baseline level. In embodiments, the imaging detection process may be used to determine a degree to which and / or an amount by which the α-Gal A or variant protein exceeds a predetermined baseline level.

[0258] In accordance, in some embodiments, a baseline or predetermined baseline level may be determined by performing the imaging detection process on a plurality of healthy subjects (e.g., subject known not to be suffering from Fabry disease) and determining respective α-Gal A levels in each of the plurality of subjects; and computing as the predetermined baseline level. EXAMPLES

[0259] Exemplary features, objects, and advantages of the present invention are apparent in the examples that follow. It should be understood, however, that the examples, while indicating embodiments of the present invention, are given by way of illustration only, not limitation. Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the examples. Example 1. Radiosynthesis of [18F]-AGAL (Compound 1)

[0260] This example summarizes the radiosynthesis of PET tracer, Compound 1 (as18F- AGAL), by the present disclosure.Attorney Docket No. MIL-029WO1 HO HO

[0261] Approximately 2000 mCi of [18F]fluoride was produced on a GE PETtrace 800 cyclotron and delivered to the18F target delivery vial of a GE FX2 N radiosynthesis module. The irradiated target water was passed through a pre-conditioned Sep-PAK Light QMA Cartridge to trap [18F]fluoride, followed by elution from the cartridge into reactor 1 using 3 mg K2CO2 and 13 mg Cryptand 222 in 0.6 mL of 50% acetonitrile (anhydrous) in water (HyClone). The contents of reactor 1 were dried via azeotropic distillation using a combination of heating, helium flow, and vacuum. An additional 1 mL of acetonitrile was introduced to reactor 1 and the azeotropic drying process was repeated. The reactor temperature was then reduced to 30 °C, followed by introduction of 4-pentynyl p-tosylate (10 mg, ABX) in 1.0 mL acetonitrile (anhydrous). The reactor was then sealed and heated to 110 °C and allowed to react with stirring for 3 minutes. Reactor 1 was then opened to reactor 2, with the reactor 1 needle in the “up” position. Helium was then introduced to reactor 1 to induce distillation from reactor 1 to reactor 2, where the distillate (18F-fluoropentyne) was bubbled through a line submerged in a room temperature (25°C) solution preloaded into reactor 2 during module set-up (300 μL 0.1M CuSO4 in water, 40 mg sodium L-ascorbate, 15 mg TBTA, 100 μL methanol, 100 μL N,N-dimethylformamide, and 0.5 mg of “Intermediate 2” shown in Figure 1 in 50 uL MeCN (anh.)). The distillation from reactor 1 was allowed to continue until the activity in reactor 2 plateaued (~1-2 minutes, 900-1050 mCi observed in reactor 2). Reactor 2 was then isolated and stirred at room temperature for 30 minutes. The contents of reactor 2 were then transferred to the HPLC pre-loading vial. Reactor 2 was then rinsed with 2 mL of water, which was then transferred to the HPLC pre-loading vial (“Tube 2” in figure 2), followed by loading onto a 5 mL HPLC Loop which had been previously filled with semi-preparative HPLC mobile phase (22% acetonitrile, HPLC, in water, HPLC) to minimize injection of air onto the HPLC column. The crude mixture was then injected on a C18 semi-preparative HPLC column (flow rate = 3.5 mL / min). The product peak (~12-13.5 minutes) was collected into a round bottom flask containing 30 mL sterile water. The contents of the round bottom flask were then passed through a preconditioned C18 Plus LightAttorney Docket No. MIL-029WO1 Sep-PAK cartridge, where18F-AGAL was trapped. The cartridge was then washed with 10 mL water (USP, sterile for irrigation), followed by elution of18F-AGAL to the FX2 N product vial using 0.5 mL ethanol. A 4.5 mL aliquot of 0.9% normal saline for injection was then passed through the Sep-PAK cartridge and into the product vial. The contents of the product vial were then transferred through a 0.2 μm air eliminating filter into a 10 mL sterile empty vial fitted with a filtered vent needle, giving 94.6 mCi of18F-AGAL in 4.5 mL (RCP = 99.07%, SA = 5595 mCi / μmol, total synthesis time = 73 minutes, n = 2).

[0262] Intermediate 1 was mixed well with 40 mg sodium L-ascorbate, 15 mg TBTA, 0.3 mL 0.1M CuSO4in water, 100 μL methanol, 100 μL N,N-dimethylformamide, and 0.5 mg of Intermediate 2 in 50 µL acetonitrile in a radiosynthesis reactor, for example GE FX2 N Module. The resulting mixture was allowed to react until the reaction was deemed complete by HPLC gamma chromatography. The product was separated by a18F Separation Cartridge, for example Sep-PAK Light QMA Cartridge, and a C-18 Cartridge, for example Sep-PAK Plus Light C18.

[0263] The average time required for the synthesis from end of bombardment (EOB) to end of synthesis (EOS) was 180 min. The average radiochemical yield (RCY) was 7% (non- decay corrected to trapped Intermediate 1). Chemical and radiochemical purities were <1% (measured with HPLC equipped with a UV detector and a gamma detector) with a specific activity (As) of 5595 mCi / µmol (EOS).

[0264] The product was formulated in 10% ethanol in normal saline (0.9%) for animal dosing. Each animal received ~ 50 – 200 uCi of [18F]AGAL administered iv. Example 2. In vitro metabolism and pharmacokinetics of [18F]-AGAL (Compound 1)

[0265] This example tested Compound 1([18F]-AGAL) for hepatic clearance and plasma stability.

[0266] Human liver microsomes, rat liver microsomes and mouse liver microsomes mixed with NADPH (Nicotinamide adenine dinucleotide phosphate) and UDPGA (uridine diphosphate glucuronic acid) were used to test hepatic clearance of compound. As shown in Table 2, hepatic clearance is low in human but high in mouse. Table 2 Human liver Rat liver microsomes Mice liver microsomes microsomes with with NADPH and with NADPH and NADPH and UDPGA UDPGA UDPGA Intrinsic Eh Intrinsic Eh Intrinsic Eh hepatic hepatic hepaticAttorney Docket No. MIL-029WO1 clearance clearance clearance (L / hr / kg) (L / hr / kg) (L / hr / kg) Cyclohexane <0.363 <0.226 10.9 0.695 17.6 0.766 fluoroalkyl derivative Dextromethorphan 2.59 0.676 38.5 0.889 33.1 0.860

[0267] To test the effects of [18F]-AGAL on the total hepatic CYP content, CYP assays were performed to access [18F]-AGAL at various concentration (0.04-30µM). No signs of inhibition to major CYPs including 1A2, 2B6, 2C8, 2C9, 2C19 and 2D6) were observed at any concentrations tested (IC50 > 30 µM).

[0268] These compounds are also stable in human blood.93% analyte remains at 30min post-injection., while only 18% analyte remains at 30min post-injection in mouse plasma (Table 3). Table 3 Analyte Half-life (Minutes) Species Cyclohexane fluoroalkyl derivative 208.00 Human plasma Cyclohexane fluoroalkyl derivative 9.83 Mouse plasma Enalapril 283.00 Human plasma Enalapril 30.60 Mouse plasma Propantheline 7.22 Human plasma Propantheline 26.00 Mouse plasma

[0269] The compound can also dissolve in non-polar solvents Lipophilicity: Log D7.4= - 0.43 in octanol / water. Example 3. Permeability of [18F]-AGAL (Compound 1)

[0270] CACO2 cells were used to tested whether [18F]-AGAL can be up-taken by cells. In this assay, 5µM [18F]-AGAL was applied to CACO2 cells. The permeability assay showed that [18F]-AGAL has low permeability in CACO2 cells. As shown in Table 4, [18F]-AGAL appears to be a substrate of P-glycoprotein (P-gp) efflux transporter, but not a substrate of BCRP (Breast Cancer Resistance Protein), another efflux transporter. Table 4 Papp Papp Ratio (B / A) A-to-B X10-6SEM B-to-A X10-6SEM cm / sec cm / sec MLN4924 (positive control for 3.37 0.42 63.40 3.30 18.8 P-gp) Nadolol (low permeability 0.36 0.02 1.45 0.03 4.1 control)Attorney Docket No. MIL-029WO1 Propranolol (high permeability 43.70 4.80 44.40 0.98 1.0 control) Minoxidil (medium 7.81 0.64 9.78 0.48 1.3 permeability control) Cyclohexane fluoroalkyl 0.11 0.02 1.36 0.04 12.0 derivative Cyclohexane fluoroalkyl 0.25 0.04 0.95 0.01 3.9 derivative +LY979 (P-gp inhibitor) Cyclohexane fluoroalkyl 0.15 0.00 1.31 0.01 8.7 derivative +KO143 (BCRP inhibitor) Cyclohexane fluoroalkyl 0.25 0.03 0.74 0.07 2.9 derivative +Elacridar (dual inhibitor of P-gp and BCRP)

[0271] A panel of cellular receptors was tested; the data show that [18F]-AGAL does not affect the activity of key cellular receptors. Example 4. [18F]-AGAL as PET tracer to measure α-Gal A levels and updates in clearance organs

[0272] This example tested [18F]-AGAL as PET tracer to measure α-Gal A levels in various organs in a Fabry disease mouse model. Drugs are cleared mainly in liver, for example, by CYP- mediated metabolism. Some are cleared by kidney and other organs. Compound clearance is important to reduce any side effects that might be caused by the drug. The uptakes of tracer [18F]-AGAL (Compound 1) in clearance organs were also measured and compared with enzyme activities.

[0273] An AAV-GLA transgene vector was administered to Fabry disease model mice (GLA-KO) 8 weeks old. [18F]-AGAL compound was then administered to Fabry mice treated with the gene therapy vector (Table 5). PET imaging at 6 weeks after AAV transduction revealed significant uptake of the tracer in the heart of the AAVGLA-treated mice, with nominal signal in the heart of wildtype and control null-vector-treated Fabry animals. PET results in treated Fabry mice showed increased signal in heart. As shown in Figure 2,the gene-therapy-treated animals had higher signal than their control counterparts at 26 weeks after administration of the AAV, demonstrating [18F]AGAL’s ability to longitudinally detect the transgene’s levels in vivo and AAV’s potential to robustly express a therapeutic protein in a major organ of interest after a single administration of the gene therapy. The PET data through ex vivo analyses at 26 weeks post-AAV injection further demonstrate that the increased PET signal in heart parallels increased serum α-Gal A activity and expression in heart of the Fabry mice treated with the gene therapy vector(Figure 3A-C). Table 5Attorney Docket No. MIL-029WO1 Group Number Treatment Wild type control 3 / (WT) GLA KO null mice control 3 rAAV9 vector only (AAVnull; i.v. (GLA- / -) (6.25e12 vg / kg) GLA KO null mice treated with Gene 3 rAAV9-GLA vector (AAVGLA) ; therapy (GLA- / -) i.v. (6.25e12 vg / kg)

[0274] The results also show that α-Gal A activity in kidneys and liver correlates with the enzyme’s activity in the serum (Figure 4A). However, the compound’s uptake in liver (Figure 4B) and kidney (Figure 4C) does not correlate with serum activity (negative to no correlation). That might be attributed to metabolism and clearance of the tracer in these clearance organs.

[0275] PET signs in vivo in major clearance organs of Fabry mice including liver and kidney were measured at week 6 and week 26 after administering the AAV vector (post-GT). Majority treated mice showed increased liver uptake of [18F]-AGAL at Week 26, while most or treated mice had comparable tracer uptake in the kidneys between weeks 6 and 26 (Figure 5A). The PET signals were also measured in heart at weeks 6 and 26. The signal changes in heart uptake correlate with changes in kidneys suggesting potential changes in renal transduction levels and enzyme retention (Figure 5B).

[0276] PET-based determination of the kinetics of [18F]AGAL in kidneys, liver, and heart was performed at weeks 6 and 26 after receiving gene therapy. The results suggest rapid kinetics of the radiotracer after intravenous administration. Importantly, there was good correlation across the organs of AAVGLA-treated mice, demonstrating the same rank order in [18F]AGAL uptake other than the kidneys of the two animals with the lowest accumulation. This may be attributed to the competing clearance and retention processes of the tracer, because the imaging data revealed that the probe primarily underwent renal clearance and elimination via the urinary bladder, while signal emanating from the intestines may suggest a secondary elimination route in mice. This is compounded by the radiotracer’s rapid kinetics after intravenous administration and physiological processes affecting uptake and elimination by the kidneys and liver in gene-therapy-treated mice (Figure 6D at 6 weeks and Figure 6E at 26 weeks after receiving gene therapy.

[0277] The ability of [18F]AGAL to interrogate the levels of α-Gal A after gene therapy was further evaluated ex vivo, by measuring the accumulated radioactivity in tissues andAttorney Docket No. MIL-029WO1 blood with a gamma counter. The data showed that there was higher uptake in the organs and blood of gene-therapy-treated Fabry mice than that of control animals (Figure 6F).

[0278] The PET scan signs in control and treated mice in heart were obtained from 0-90 minutes after [18F]AGAL dosing at weeks 6 and 26. [18F]-AGAL time activity curves are shown in Figures 6A-6C. Increased uptake of the tracer was observed in the heart of the gene-therapy-treated animals, while lower uptake of the tracer was observed in Fabry mice treated with a vector that did not encode alpha Galactosidase A (Figure 6B (6 weeks after receiving gene therapy) and Figure 6C (26 weeks after receiving gene therapy). There was a decrease in heart uptake of [18F]AGAL in gene-therapy-treated mice on week 24-26, due to lower expression of alpha Galactosidase A (Figure 6C). Analyses of time-activity uptake data showed no apparent differences in [18F]AGAL’s cardiac uptake at 6 and 26 weeks in wild- type and AAVnull-treated mice (Figures 6B and 6C). [18F]AGAL predominantly cleared through the renal and bladder route.

[0279] Cardiac tissues were collected from mice 26 weeks post-GT after last PET scan. The collected cardiac tissues were used for ex vivo evaluation.35nM [18F]-AGAL were diluted in Mcllvair (pH5.0) or in Tris-Saline (pH7.0) buffer for analysis. Representative autoradiography images of murine heart slices incubated with 35 nM of [18F]AGAL at the corresponding pH are shown in Figure 7A. The images indicate that the probe binds to the enzyme in acidic conditions (pH 5.0). Minimal binding of [18F]AGAL was observed in the heart tissues of wild-type mice, and Fabry (GLA KO) mice that were dosed with the control null vector not encoding a therapeutic protein. Quantification of the autoradiography data identified that the probe had 262-fold higher specific binding in heart tissues from the AAVGLA-treated mice than the corresponding controls. Cardiac tissues from GT-treated mice displayed 261-fold and 300-fold higher specific signal than WT and control GLA-KO mice (Figure 7B). Using cardiac tissue sections from AAVGLA-treated animals, the inventors further determined at two different concentration ranges that the probe has a dissociation constant KD of ~ 20 nM for its target at pH 5.0 (Figure 8A and 8B). Pet tracer’s binding was significantly blocked (81%) by cold [18F]-AGAL at pH5.0.

[0280] [18F]-AGAL Kd was estimated by saturation analysis (Figure 8A and 8B). The Kd (about 20 nM) aligns with IC50of Aziridine and Bodipy-Aziridine for agalsidase beta ERT (4-mu hydrolysis). The results determined that this probe could detect human α-Gal in cardiac tissue of AAVGLA-transduced mice (Figures 7 & 8). The results also suggest that the radiolabeling strategy discussed herein did not affect the probe’s affinity to its target enzyme.Attorney Docket No. MIL-029WO1

[0281] In addition to the heart, the data also demonstrate that [18F]AGAL could detect its enzyme target in the liver and kidney tissue sections of AAVGLA-transduced Fabry mice and maintain its pH-dependent binding (as shown in Figure 7C and 7D). Example 5. [18F]-AGAL as PET tracer to track α-Gal A specifically in organs in mice

[0282] GLA-KO mice were divided into three groups and administered the AAV vector as shown in Table 6. Mice were administered with an AAV9-GLA gene therapy vector (2.5 × 1011vg / kg) at the age 8-12 weeks old and were euthanized at the indicated time for each study. Table 6 Group rAAV9- Baseline Blocking D3 Baseline Blocking D31 GLA D0 D28 (Day -28) Baseline Follow-up Follow-up Follow-up Imaging Imaging imaging (Day 3) Imaging (Day 31) (Day 0) (Day 28) A (GLA 2.5e11 [18F]- [18F]-AGAL [18F]-AGAL [18F]-AGAL KO mice) vg / kg; i.v. AGAL (N=3) B (GLA 2.5e11 [18F]- [18F]-AGAL & α- [18F]-AGAL [18F]-AGAL & α-Gal A KO mice) vg / kg; i.v. AGAL Gal A chaperon . chaperon 1mg / kg by (N=3) 1mg / kg by i.v. i.v. (30 min after [18F]- (10-15 min prior AGAL) to [18F]-AGAL) C (GLA 2.5e11 [18F]- [18F]-AGAL [18F]-AGAL [18F]-AGAL KO mice) vg / kg; i.v. AGAL + + (N=3) [18F]-AGAL & [18F]-AGAL & cold cold [F]AGAL. [F]AGAL.1mg / kg by 1mg / kg by i.v. i.v. (30 min after [18F]- (10-15 min prior AGAL) to [18F]-AGAL)

[0283] A non-radioactive [19F]AGAL , and an α-Gal A chaperon , which similarly binds to α-Gal A’s active site, was used to determine the specificity of the in vivo association of [18F]AGAL to α-Gal A. Fabry mice were imaged four weeks after AAV administration on two different days, obtaining a baseline reading on Day 0 and a follow-up scan on Day 3 where the blocking agent was dosed 15 minutes before injection of [18F]AGAL. The heterologous blocking with the α-Gal A chaperon and homologous blocking with [19F]AGAL successfully blocked binding of the radiotracer by more than 75% in the heart of the AAVGLA-treated Fabry mice (Figure 9A).

[0284] In vivo PET imaging using [18F]-AGAL as tracer showed that the PET tracer’s binding to α-Gal A is displaceable by the probe’s cold form [19F]-AGAL or an α-Gal AAttorney Docket No. MIL-029WO1 chaperon (e.g., a pharmacological chaperone that binds to the active site of α-Gal A (Figure 10).

[0285] Changes in SUVmean30-60of heart and liver from baseline imaging by blocking via self-blocking or heterologous blocking are shown in Figures 11A and 11B, respectively. Changes in AUC30-60 of heart and liver from baseline imaging by blocking via self-blocking or heterologous blocking are shown in Figures 12A and 12B, respectively. Figure 12A shows the specificity of [18F]AGAL binding in the heart. Figure 12B shows In vivo determination of the specificity of [18F]AGAL binding in the liver of gene-therapy-treated Fabry (GLA-KO) mice. These data suggest that [18F]AGAL specifically binds to the α-Gal A’s active site in vivo.

[0286] Ex vivo autoradiography also confirmed the in vivo imaging data, with the heart and liver sections of AAVGLA-treated mice demonstrating elevated [18F]AGAL binding (Figures 13A and 13B). As these animals were dosed with blocking agents, the heart signal was lower by ~ 80% compared to previous autoradiographic evaluation (Figure 7B), which aligns with the reduction observed in SUV (Figures 11A and 11B).

[0287] To further deduce how [18F]AGAL binds to its target in vivo, the tracer was administered to mice 30 minutes before dosing the blocking agent. PET-derived time-activity curves of the heart showed high uptake in AAVGLA-treated mice, indicating that [18F]AGAL likely binds covalently to α-Gal A (Figures 14A and 14B). Evaluation of the heart time- activity uptake curves in GLA-KO mice after receiving gene therapy, where [18F]AGAL was administered after the blocking agent showed similar results (Data not shown). Taken together, these studies showed that the probe specifically binds to α-Gal A, making it a translational pharmacokinetic biomarker.

[0288] These data demonstrate that [18F]AGAL is a promising PET tracer for the detection and longitudinal tracking of α-Gal A expression in the heart following gene therapy in a mouse model of Fabry disease. Imaging findings showed good correlation with confirmatory ex vivo biochemical assays. [18F]AGAL demonstrates specificity, mechanism of target binding, and kinetics that are suitable for use as a pharmacokinetic / pharmacodynamic biomarker in gene therapy trials of patients with Fabry disease. Example 6: Comparison of [18F]AGAL uptake in gene-therapy- vs enzyme-replacement- treated Fabry mice

[0289] In this study, [18F]AGAL and PET imaging was used to compare enzyme replacement therapy (ERT) and gene therapy in Fabry disease. A set of GLA KO mice wereAttorney Docket No. MIL-029WO1 transduced with AAVGLA (Day -28), and after 28 days they were imaged on two consecutive days with a first scan on Day 0 and a follow-up scan on Day 1.

[0290] Enzyme Replacement Therapy (ERT) was administered in a separate set of Fabry mice immediately after the imaging session of Day 0 (baseline scan) and 24 hours before the imaging session on Day 1, to recapitulate the α-Gal A levels observed in tissue and circulation after ERT in the clinic.

[0291] PET imaging showed enhanced uptake of [18F]AGAL in the heart of the AAVGLA- treated Fabry mice (Figure 15A). There was minimal uptake of the tracer in the heart of wildtype and ERT-treated Fabry mice (Figure 16A). No difference in the tracer’s heart uptake before or after ERT was observed, in line with the clinical observations that ERT does not achieve reintroduction of α-Gal A in the heart. Only small increases in [18F]AGAL’s uptake were observed in the liver and kidney after ERT (Figures 16B and 16C). Uptake of [18F]AGAL was only observed in the lung of gene-therapy-treated mice, but not in wildtype and ERT-receiving animals, which may be attributed to transduction of the lung or uptake of α-Gal A via a compensatory cross-corrective mechanism, such as the liver and heart secreting α-Gal A in circulation (Figure 16D). Significant bladder and gallbladder uptake in all cohorts was observed (Figures 16E and 16F), indicating that the tracer is eliminated primarily through the urinary bladder and in lower extent via biliary excretion, potentially due to [18F]AGAL’s size and lipophilicity.

[0292] The in vivo imaging data were confirmed through biochemical analyses of the hearts at the end of the study to establish in vivo and in vitro correlations. The studies determined that gene-therapy-treated animals had approximately 400 times more α-Gal A than ERT animals (Figure 15B). These data agreed with immunohistochemical results that showed modest uptake of α-Gal A by cardiomyocytes 24 hours after ERT, in contrast to the wider expression the protein in the heart of gene-therapy-treated Fabry mice (Figures 17 and 18). Comparison of the rank orders of the [18F]AGAL cardiac uptake vs α-Gal A’s enzymatic activity in the heart tissue showed excellent correlation (Figure 15C), demonstrating that PET imaging can potentially provide critical information for transgene expression during Fabry gene therapy.

[0293] The inventors further evaluated the tracer’s retest variability in AAVGLA-treated mice that were imaged on two consecutive days. The data indicate that [18F]AGAL exhibited a retest variability less than 10% in the heart and approximately 10% in the liver (Figure 19), indicating that is an excellent PET tracer.Attorney Docket No. MIL-029WO1 Example 7: Evaluation of [18F]AGAL’s in non-human primate (NHP)

[0294] This study evaluated [18F]AGAL in non-human primate (NHP) to support [18F]AGAL’s clinical translation. In this study, the inventors evaluated radiotracer [18F]AGAL in a healthy NHP, to obtain pharmacokinetics and radiation dosimetry estimates in a higher species for potential translation to humans.

[0295] One healthy non-naïve male rhesus monkey (Macaca mulatta, 11.3 kg, 7.4 years old) was used in this study. The animal was induced first and then administered with [18F]AGAL. The radiotracer was administered in a single intravenous (IV) dose as a bolus over 3 minutes using an infusion pump in a volume of 9.7 mL. PET imaging was conducted over ~250 minutes immediately following injection of [18F]AGAL (6.81 mCi; 252.07 mBq). Prior to the radiotracer injection, a CT scan was performed for attenuation correction and anatomical identification. Immediately following injection of the radiotracer, dynamic emission data were collected using continuous bed motion (CBM) acquisition for ~250 minutes and binned into a series of 24 dynamic 3D PET image volumes. The generated PET images were subsequently reconstructed with standard corrections. Reconstructed PET images were analyzed using the image processing software. The following organs were considered as source organs for the purpose of dosimetry calculations: heart, liver, gallbladder, kidneys, intestines, urinary bladder, lumbar vertebrae, lungs, and testes. The number of disintegrations per unit activity administered in each source organ (i.e., kinetic values), τ, were computed from the area under the non-decay corrected TACs via trapezoid method. Area under the curve from end of imaging to infinity was computed with the assumption of physical decay only following the last imaging time point. The kinetic values were converted to adult human values by using conversion factors based on differences in organ and body weights between the two species.

[0296] ICRP 100 HAT gastrointestinal (GI) tract model was used to estimate the kinetic values in the intestinal segments, assuming the activity enters the GI tract via small intestine, with no reabsorption. The intestinal decay corrected time-activity curve was used for estimation of the fraction of the radioactivity entering the intestine during the imaging period. To conservatively estimate the whole-body red marrow content the measured lumbar marrow was multiplied by 10 / 4 based on previously reported values of red marrow mass in the vertebrae of rhesus and human subjects. The effective doses were evaluated based on ICRP- 89 adult male model according to the ICRP Publication 103 (2007).Attorney Docket No. MIL-029WO1

[0297] The data suggest that, like its uptake in wildtype and untreated Fabry mice, [18F]AGAL showed high uptake in the kidneys and urinary bladder of the NHP, demonstrating elimination predominantly via urinary pathway, with a small hepatobiliary component (Figure 20). Time-activity uptake curves (TACs) further confirmed the quick clearance of the tracer from the kidneys to the urinary bladder. The liver and heart were the non-elimination organs with the highest uptake with a relatively slower washout kinetics. Lower uptake with reversible kinetics and moderate washout was observed in the testes and lumbar vertebrae (marrow) (as shown in Figure 21) Using the non-decay corrected TACs, kinetic values for source organs were determined that showed the three organs with largest kinetic values were urinary bladder, small intestine, and kidneys (Table 7). The kinetic values were scaled based on differences in organ and body weights between human and rhesus monkey. Urinary bladder was modeled with a voiding interval of 2 hours. Table 7. [18F]AGAL kinetic values (or total number of disintegrations) in source organs of a male rhesus macaque Source OrganKinetic Value (MBq-h / MBq)Gallbladder Cont. 1.43E-03 Left colon 1.72E-02 Small Intestine 1.76E-01 Right colon 9.54E-02 Rectum 3.10E-03 Heart Wall 1.99E-02 Kidneys 1.18E-01 Liver 2.22E-02 Lungs 1.57E-02 Red Marrow 6.56E-03 Testes 5.15E-04 Urinary Bladder Cont. 8.22E-01 Remainder 2.72E-01

[0298] Radiation dosimetry estimates were calculated utilizing the kinetic values in the ICRP-89 adult male model. The estimated whole-body effective dose (ED ICRP-103) was 0.0256 mSv / MBq, in line with other18F-labeled PET tracers (References). Urinary bladder wall received the highest organ dose (4.03E-01 mSv / MBq) based on a urinary bladder voiding model with 2-hour voiding interval (Table 8). Although the highest dose organ is the urinary bladder limiting the number of [18F]AGAL injections to two per year at 185 MBq (5 mCi / injection) or five per year at 74 MBq (2 mCi / injection) according to 21 CFR 361.1, voiding the bladder immediately after the scan may be mitigate the radiation exposure.Attorney Docket No. MIL-029WO1 Table 8. Radiation dosimetry estimates for [18F]AGAL in an adult human model (ICRP-89) Target Organ Radiation Dose (mSv / MBq) Adrenals 1.30E-02 Brain 1.25E-03 Esophagus 3.23E-03 Eyes 1.28E-03 Gallbladder Wall 1.10E-02 Left colon 2.78E-02 Small Intestine 5.50E-02 Stomach Wall 4.09E-03 Right colon 6.46E-02 Rectum 2.58E-02 Heart Wall 1.26E-02 Kidneys 7.35E-02 Liver 6.87E-03 Lungs 4.01E-03 Pancreas 8.42E-03 Prostate 3.02E-02 Salivary Glands 1.47E-03 Red Marrow 6.08E-03 Osteogenic Cells 4.12E-03 Spleen 5.60E-03 Testes 9.51E-03 Thymus 2.64E-03 Thyroid 1.78E-03 Urinary Bladder Wall 4.03E-01 Total Body 6.94E-03 ED (ICRP-103) 2.56E-02

[0299] The data in NHP suggest that [18F]AGAL has an acceptable dosimetry that accommodates imaging for several times in a year if needed, thus making [18F]AGAL a clinically translatable biomarker for the long-term monitoring of Fabry gene therapy. It provides a useful tracer to detect the levels of active α-Gal A in target tissues of Fabry disease patients, and to monitor treatment effect in clinical therapeutic trials. Example 8. Methods and materials Recombinant AAV Information

[0300] Recombinant AAVGLAthat encodes the human α-galactosidase gene (GLA; NM_000169) and AAVnullwhich comprises a non-coding DNA sequence were prepared and characterized. The genome titer was determined by ddPCR, the purity was assessed by eitherAttorney Docket No. MIL-029WO1 SDS-PAGE followed by silver staining or CE-SDS to visualize VP1, VP2 and VP3, and the absence of endotoxin was assessed by a limulus amebocyte lysate assay (Endosafe). The aliquoted AAVs were stored at – 80oC until further use. Animal Studies and Tissue Processing

[0301] The Fabry mouse colony was maintained and followed Animal Welfare and Institutional Animal Care and Use Committee Review guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC). Male mice were injected with AAV test articles at the age 8-12 weeks old and were euthanized at the indicated time for each study. Blood was collected via cardiac puncture and processed to separate serum. Mice were transcardially perfused with PBS for 4-5 minutes or until the liver was cleared of blood prior to tissue collection. Tissues and serum for analytical endpoints were harvested and snap- frozen, followed by cryopreservation in -80oC. Tissues were prepared for α-Gal activity through homogenization with appropriately sized beads, tubes, and lysis buffer volumes (10 mM HEPES, 0.5% TritonX-100, 1X protease inhibitors). Supernatant from tissues was collected and evaluated by the α-Gal enzyme activity assay. α-Gal Enzyme Activity

[0302] Alpha-galactosidase A activity was determined using the 4-MU-α-gal fluorescent substrate. Briefly, a biological sample (serum or tissue homogenate) of 2 μL was incubated with 15 μL 4-MU-α-gal substrate solution with α galactosidase B inhibitor at 37 °C for 60 minutes. The enzymatic reaction was stopped by addition of 200 μL glycine carbonate stop solution, pH 10.7. The fluorescence of the 4-MU product at 465 nm was measured followed excitation at 360 nm, using a fluorescence plate reader. The concentrations of 4-MU in testing samples were calculated from the 4 MU calibration curve in the same plate. Serum and tissue α-Gal activity was normalized to the volume of serum, or tissue’s total protein concentration that was determined by the BCA assay and expressed as nmol of 4-MU substrate produced per hour per mL of serum or mg of total protein. PET / CT Imaging and PET Image Date Analysis

[0303] PET imaging with [18F]AGAL and CT were performed on dedicated small-animal PET scanners (Siemens Multimodality Inveon, Siemens Medical Solutions USA, Inc. or Molecubes β-Cube and X-Cube, Molecubes Inc.). The mice were anesthetized using isoflurane / medical air inhalation prior to the radiotracer injection and throughout the scan duration. During anesthesia, warming was provided to maintain healthy core body temperature. [18F]AGAL was administered as a bolus intravenous (IV) injection via the lateral tail vein (1.85 – 7.40 MBq / 50 – 200 µCi). Dynamic scans were acquired in list modeAttorney Docket No. MIL-029WO1 format over 90 minutes, and the collected data were then sorted into 0.5-mm sinogram bins for image reconstruction using FORE / 3D-OSEM-MAP. Following the PET acquisition, a low dose CT scan was acquired (80 kVp, 0.5 mA) for anatomical reference and to provide guidance for the delineation of selected tissues regions of interest (ROI). Wherever indicated, static whole-body scans were performed 30 minutes after [18F[AGAL administration, with the energy window spanning 420 – 580 keV via continuous-bed motion acquisition. An α-Gal A chaperon or [19F]AGAL (MedChem Imaging Inc.) (a homologous blocking agent) were administered as a bolus IV injection at 1 mg / kg either 15 minutes before (blocking study) or 30 minutes after (chase study) the dosing of the [18F]AGAL. Animals receiving enzyme replacement therapy were dosed IV with 1 mg / kg recombinant human alpha galactosidase A (Takeda) 24 hours before PET imaging, which is equivalent to the dose used for treating patients with Fabry disease.

[0304] For dynamic scans, PET list mode data were reconstructed using ordered subset expectation maximization (OSEM) into a series of 36 frames (4 × 15, 5 × 60 and 27 x 120 sec), with corrections for attenuation, randoms, scatters, dead time, radioactive decay and detector normalization. For static scans, PET data were reconstructed in a single frame using the same algorithm. Reconstructed images had dimensions of 192 × 192 × 384, pixel sizes of 0.4 × 0.4 × 0.4 mm and units of kBq / cc. PMOD 4.2 software (PMOD Technologies LLC) was used to visualize and quantify the PET data. Volumes of interest were manually drawn over the heart, liver, lung, kidney, femur, muscle (quadricep), gallbladder and bladder. Time activity curves were generated for dynamic studies and uptake in each tissue was expressed in units of SUV based on injected activity dose and most recently recorded animal weights. Immunohistochemistry

[0305] The dissected tissue samples were trimmed and fixed. Five (5) µm tissue sections were collected for immunohistochemistry (IHC) assay. The section was pre-treated for 20 minutes using heat mediated-antigen retrieval with Bond epitope retrieval solution 1 (pH 6.0, Catalog No. AR9961, Leica Biosystems), followed by incubation with the α-Gal antibody (4.9 µg / mL, Lot SH006, Takeda) for 30 minutes at room temperature and detected using horseradish peroxidase (HRP) conjugated compact polymer system.3,3'-diaminobenzidine (DAB) was used as the chromogen, and the sections were then counterstained with haematoxylin and were further processed for imaging. Autoradiography

[0306] Following perfusion, the heart, liver, and kidneys were resected and subsequently frozen for cryosectioning. The tissue sections at a thickness of 10 μm were prepared andAttorney Docket No. MIL-029WO1 stored at −80 °C for later use. Prior to autoradiography, the tissue sections were acclimated to room temperature. To evaluate specific binding in the presence of acidic or physiological pH, [18F]AGAL was prepared by diluting stock into McIlvaine buffer (0.15 M Citrate-Phosphate buffer), pH 5.0 or 50 mM Tris-HCl in 0.9% saline, pH 7.45. In initial assay optimization studies 35 nM of [18F]AGAL was used, and all other studies utilized 3 nM of [18F]AGAL. Non-specific binding was defined by incubation of tissue slides with or without 1 mM [19F]AGAL. An equivalent volume of 100% DMSO was added (<0.1% final amount) to the incubation bath defining total binding. For saturation analysis, increasing concentrations of [18F]AGAL (0.5 - 185.6 nM) were added to McIlvaine buffer (pH 5.0) and split between two troughs per concentration. Tissues were incubated in the presence or absence of [19F]AGAL then for 60 minutes at 23oC and reactions were terminated. Following exposure to phosphor screens (BAS-IP TR2040E; Cytiva; Marlborough, MA) for 30-60 minutes, digital images were generated by scanning at 200-mm pixel size using an AmershamTMTyphoonTM5 (Cytiva; Marlborough, MA). Region of Interest (ROI) analysis was performed using MCID 7.1 (Interfocus Imaging, Cambridge, UK). Data are reported in percent specific binding or molecular density calibration units / mm2(MDC / mm2) and graphically analyzed using Graphpad Prism 9.2.0 (GraphPad Software, San Diego, CA). The KDand Bmax, were estimated by first calculating the specific binding using the formula Total Signal – Signal due to Non-specific Binding = Signal due to specific binding, and then fit the resulting data to the non-linear regression equation Y=Bmax*X / (KD+ X) for one-site specific binding, with the specific binding plotted on the Y axis and the corresponding [18F]AGAL concentration on the X axis. EQUIVALENTS AND SCOPE

[0307] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above description, but rather is as set forth in the following claims.

Claims

Attorney Docket No. MIL-029WO1 CLAIMS 1. A compound for use in tracing alpha-galactosidase A or variant thereof, wherein the compound has a structure according to Formula I, HO (Formula I),wherein each of L1and L2is independently an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety.

2. The compound of claim 1, wherein A is a heterocylic compound comprising 1-3 nitrogen atoms.

3. The compound of claim 2, wherein A is 1,2,3-triazole formed from an alkyne and an azide moiety.

4. The compound of claim 1, wherein A is formed from a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction or an inverse-electron-demand Diels–Alder (IEDDA) reaction.

5. The compound of claim 1, wherein the compound of Formula I is formed from an azide- HO containing compound of Formula (Formula II), and an2 R alkyne-containing compound of Formula III,L(Formula III).Attorney Docket No. MIL-029WO1 6. The compound of any one of claims 1-3, wherein the compound has a structure according to Formula I-A, HO (Formula I-A).

7. The compound of any one of claims 1-5, wherein: L1is a C1-C10alkylene; and / or L2is a C1-C5 alkylene linker or a 6-20 membered heteroalkylene comprising one or two amide moieties.

8. The compound of claim 6, wherein L1 CHis2 n, wherein n is an integer of 1-10; and O wherein m is an integer of 1-5, o is an9. The compound of any one of claims 1-7, wherein R is a radioactive moiety for use in positron emission tomography (PET).

10. The compound of claim 8, wherein R is or comprises a moiety selected from18F,64Cu, 89Zr,111In,99mTe,11C,14C,124I,123I,131I,15O,13N and82RbCl.

11. The compound of claim 1, wherein the compound of Formula I is 2-(4-(3-(fluoro- 18F)propyl)-1,1,1,1,1,1-hexamethyl-1H-1λ9,2,3-triazol-1-yl)-1-((1S,2S,3S,4S,5R,6S)-Attorney Docket No. MIL-029WO1 2,3,4-trihydroxy-5-(hydroxymethyl)-7-azabicyclo[4.1.0]heptan-7-yl)ethan-1-one (Compound 1).

12. The compound of claim 1, wherein the compound has a structure of HO (Compound 1).

13. A radiolabeled protein, wherein said radiolabeled protein is formed by contacting a protein of interest with a compound according to Formula I as described in any one of claims 1-12.

14. The radiolabeled protein of claim 13, wherein the said radiolabeled protein has a structure according to Formula IV, Protein (Formula IV),wherein each of L1and L2is independently an optionally substituted C1-C20alkylene or a 2-20 membered heteroalkylene; A is a moiety formed from a bioorthogonal chemical reaction; and R is a radioactive moiety.

15. The radiolabeled protein of claim 14, wherein A is a heterocylic compound comprising 1- 3 nitrogen atoms.Attorney Docket No. MIL-029WO1 16. The radiolabeled protein of claim 15, wherein A is 1,2,3-triazole formed from an alkyne and an azide moiety.

17. The radiolabeled protein of claim 15, wherein A is formed from a strain-promoted azide- alkyne cycloaddition (SPAAC) reaction or an inverse-electron-demand Diels–Alder (IEDDA) reaction.

18. The radiolabeled protein of claim 14, wherein L1is a C1-C10alkylene; and / or L2is a C1-C5 alkylene linker or a 6-20 membered heteroalkylene comprising one or two amide moieties.

19. The radiolabeled protein of claim 14, wherein R is or comprises a moiety selected from 18F,64Cu,89Zr,111In,99mTe,11C,14C,124I,123I,131I,15O,13N and82RbCl.

20. The radiolabeled protein of any one of claims 13-19, wherein R is18F.

21. The radiolabeled protein of claim 14, wherein the said radiolabeled protein is formed by contacting a protein of interest with a compound of Formula I that is Compound 1, wherein the said radiolabeled protein has a structure according to Formula I-A-1, Protein (Formula I-A-1).

22. The radiolabeled protein of any one of claims 13-21, wherein the protein is an α-Galactosidase A or a variant thereof.

23. A modified protein, wherein said modified protein is formed by contacting a protein of interest with a compound according to Formula II,Attorney Docket No. MIL-029WO1 HO (Formula II), wherein L1is an optionally substituted C1-C20or a heteroalkylene. CH24. The modified protein of claim 23, wherein L1is2 n, wherein n is an integer of 1-10.

25. The modified protein of claim 23, wherein n is 7.

26. The modified protein of any one of claims 23-25, wherein the protein is an alpha- galactosidase A or a variant thereof.

27. A radiolabeled protein, wherein said radiolabeled protein is formed by contacting the modified protein of any one of claims 23-26 with a compound according to Formula III, 2 R H L(Formula III), whereinL2is an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene; and R is a radioactive moiety.

28. The radiolabeled protein of claim 27, wherein R is or comprises a moiety selected from 18F,64Cu,89Zr,111In,99mTe,11C,14C,124I,123I,131I,15O,13N and82RbCl.

29. The radiolabeled protein of any one of claims 27-28, wherein R is18F.

30. A method for measuring alpha-galactosidase A or variant thereof in vivo, the method comprising: (a) administering a compound of any one of claims 1-12 to a subject in need thereof; and (b) detecting a radioactive signal present in a target tissue of the subject based on the formation of the radiolabeled protein of claim 22.Attorney Docket No. MIL-029WO1 31. The method of claim 30, wherein the administered compound is Compound 1, HO (Compound 1).

32. A method for measuring alpha-galactosidase A or variant thereof in vivo, the method comprising: (a) administering a compound of Formula II to a subject in need thereof, wherein said compound of Formula II has the following structure, HO (Formula II), wherein L1is an optionally substituted C1-C20or a heteroalkylene; (b) administering a compound of Formula III to said subject, wherein said compound of R Formula III has the following structure,H L(Formula III), wherein L2is an optionally substituted C1-C20 alkylene or a 2-20 membered heteroalkylene and R is a radioactive moiety to form a radiolabeled protein according to claim 22; and (c) detecting a radioactive signal present in a target tissue of the subject based on the formation of the radiolabeled protein of claim 22.

33. The method of any one of claims 30-32, wherein the expression level of alpha- galactosidase A or variant thereof in a target tissue is measured.

34. The method of any one of claims 30-32, wherein the enzymatic activities of alpha- galactosidase A or variant thereof in a target tissue is measured.Attorney Docket No. MIL-029WO1 35. The method of any one of claims 30-34, wherein the subject has Fabry disease.

36. The method of claim 35, wherein the subject receives an alpha-galactosidase A gene therapy.

37. The method of claim 36, wherein the gene therapy comprises an AAV vector comprising a gene encoding alpha-galactosidase A or a functional variant thereof.

38. The method of any one of claims 30-37, wherein the target tissues include heart, liver, lung, kidney, brain, spinal cord, stomach and gastrointestinal tract.

39. The method of any one of claims 36-38, wherein the alpha-galactosidase A is measured about 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months or more after the subject receives the alpha-galactosidase A gene therapy.

40. The method of any one of claims 33-36, wherein the alpha-galactosidase A or variant thereof is measured before the subject receives the alpha-galactosidase A gene therapy.

41. The method of any one of claims 30-40, wherein the radioactive signal in the target issue is obtained by imaging the target tissue.

42. The method of claim 41, wherein the imaging is positron emission tomography (PET) imaging.

43. The method of claim 42, wherein the imaging is real time.

44. The method of any one of claims 30-43, wherein the relative amount of the radioactive signal in the target tissue is determined.

45. The method of any one of claims 30-32, wherein the level of alpha-galactosidase A or variant thereof in a target tissue is measured after an enzyme replacement therapy.

Citation Information

Patent Citations

  • Composition and methods for the treatment of fabry disease

    WO2022183052A1

  • ACTIVITY BASED PROBES (ABPs) INTERACTING WITH GLYCOSIDASES

    WO2011112085A1

  • Conduritol aziridine derivatives and uses thereof

    WO2019075574A1